C. diff. Spores and More: Recent Episodes
Nancy C. Caralla
“C. diff. Spores and More” is an educational program providing you with up-to-date information pertaining to C. diff. and Healthcare-Associated infections. Raising awareness through education and advocacy saves lives worldwide. Topics are of C. difficile infection (CDI) prevention, treatments, and environmental safety products along with Healthcare-Associated Infection (HAI) awareness and more. Our guests are topic experts discussing Antibiotic Resistance, Research and Development, Clinical trials, Nutrition Counseling, Microbiome, Mental health, C. diff. survivors, and so much more. Please join us every Tuesday at 10 AM Pacific Time on the VoiceAmerica Health and Wellness Channel.
Join us with our guest, Professor Simon Cutting, Ph. D., as we discuss the genetic control of spore formation in Bacillus subtilis, and the research behind the scenes defining Clostridioides difficile in health and environment.
Join us with our guest, Ron Roman, RN, CEO Safety Net as we discuss creating a safe environment, maintaining a safe environment in both healthcare and home. Ron will review Disinfection – what is Clean, Sanitize, Disinfect and Sterilize and how to simplify the terms.
Join us with three C. diff. Survivors - Christine, Alba, and Renata, as they share their personal message with you.
We are grateful for their time and for sharing their C. diff. infection experiences with us.
A Symposium specifically developed for Patients Diagnosed With a C. diff. Infection, Being Treated For a Clostridioides diffiicile infection, Recovering From a Clostridioides difficile Infection and Recurrences with Family Members and Caregivers. Distinguished members and keynote speakers provide insight as to what impacts the patient and families on both quality and economic topics, what role leadership plays in creating the right culture for patient-centered care, and how to identify, evaluate, and prioritize innovations that can quickly touch the lives of patients battling C. diff. infections.
Kathy Bischoff, C. diff. Survivor My C. diff. Journey
Renata Johnson, C. diff. Survivor My C. diff. Journey
Paul Feuerstadt, MD - review
Barbara McGovern, MD, “Treatment of recurrent C. difficile infection with SER-109, an investigational microbiome drug.
A Symposium specifically developed for Patients Diagnosed With a C. diff. Infection, Being Treated For a Clostridioides diffiicile infection, Recovering From a Clostridioides difficile Infection and Recurrences with Family Members and Caregivers. Distinguished members and keynote speakers provide insight as to what impacts the patient and families on both quality and economic topics, what role leadership plays in creating the right culture for patient-centered care, and how to identify, evaluate, and prioritize innovations that can quickly touch the lives of patients battling C. diff. infections.
Courtney Jones ” Microbiome, Microbiota, and Gut Health.” Denise Cardo, MD “Everyone Has a Role in Antibiotic Awareness.” Larry Kociolek, MD “C. diff. Infections in Pediatrics.”
This event was sponsored by Seres Therapeutics. Seres Therapeutics mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics
Enjoy the program!
Welcome to the second episode of a special four (4) part series: A Symposium Created For Patients Diagnosed With a C. diff. Infection, Being Treated For a Clostridioides diffiicile infection, Recovering From a Clostridioides difficile Infection and Recurrences with Family Members and Caregivers. Welcome to a Symposium specifically developed for patients, families, and caregivers. The Patient & Family C. diff. Symposium: where a gathering of healthcare professionals, keynote speakers, health advocates, practitioners, educators, are transforming the patient experience, and changing the way people experience C. diff. infections worldwide. Simon Cutting, Ph. D. “Bacillus, and C. diff. Spore Overview. “ Teena Chopra, MD ” Introduction to Infection Prevention.” Doe Kley, RN, MPH “C. diff. Transitioning from Hospital to Home. This event was sponsored by Seres Therapeutics, Seres Therapeutic's mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics Enjoy the presentations by the topic leaders joining us!
The Patient & Family C. diff. Symposium: A gathering of healthcare professionals, keynote speakers, health advocates, practitioners, educators, thought leaders, and patients who are transforming the patient experience, and changing the way people experience C. diff. infections worldwide.
Program Presenter: Paul Feuerstadt, MD, FACG
Barbara McGovern, MD “Treatment of recurrent C. difficile infection with SER-109, an investigational microbiome drug.” Paul Feuerstadt, MD ” C. diff. Overview – What is a C. diff. Infection?” Sahil Khanna, MBBS, “C. diff. Treatments and FMT Overview. “
Dr. Tamas Haidegger, Ph. D., Associate Professor Obuda University, and Co-founder: HandInscan will be discussing the importance of not only hand-washing but how Hand Hygiene is the top priority in social safety. Hand Hygiene remains the number one infection prevention action individuals can utilize worldwide to prevent the spread of germs and viruses worldwide. Dr. Haidegger will also introduce the research and science behind the HandInScan - an objective hand hygiene control in the medical environment.
Join us with our guest Dr. Robert Carman, Ph. D., Director of Microbiology at TECHLAB, Inc. Dr. Carman's research focuses on Clostridioides difficile (C. diff., C. difficile, CDI). Dr. Carman not only introduces us to the gut microbiome, but explains the details of the environment, the colonies of microorganisms, bacteria, viruses, protozoa, and fungi, that are present in the gastrointestinal tract
Metronidazole For the Treatment of C. difficile Infections: On the Way Out? - Presented by: Wiep Klaas Smits, Ph. D., Department of Medical Microbiology Leiden University Medical Center. A Four-pronged Threat: Clostridioides difficile Infection (CDI), Antibiotics, the Flu Season, and COVID-19.” - Presented by: Dr. David Lyerly, Co-founder and Chief Science Officer of TECHLAB, Inc. Aerosol Transmission of Pathogens: The Problem and the Solutions. Presented by: Maureen Spencer, RN, M.ED., CIC
Inaugural Dale Gerding Lifetime Achievement Award - Presented by Sahil Khanna, MBBS MS, Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic to Dale Gerding, MD, FACP, FIDSA. Adjunctive Therapy for CDI to Prevent Recurrence: Practical Issues. - Presented by: Dr. Dale Gerding, MD, FACP, FIDSA, Retired Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Research Physician at the Edward Hines Jr. VA Hospital. “Antimicrobial Stewardship and Its Impact On C difficile.” - Presented by: Glenn Tillotson, PHD, FIDSA, FRSM,, FCCP, FISC, Senior Consultant, Global ID, Anti-Infective Drug Development, GST Micro LLC. Metronidazole For the Treatment of C. difficile Infections: On the Way Out? - Presented by: Wiep Klaas Smits, Ph. D., Department of Medical Microbiology Leiden University Medical Center
“Introducing a New Disinfection Technology Against C. diff.” Jordan Bastian (Speaker) Infection Preventionist, CloroxPro Clinical and Scientific Affairs, Clorox Company
Ibezapolstat Update: Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect? Kevin Garey (Speaker) Chair of the Department of Pharmacy Practice and Translational Research and Professor of Pharmacy Practice, University of Houston College of Pharmacy
More Than a CDI: The Revolving Door and a Ray Of Hope. Kathy Bischoff (Speaker) Coordinator, VHA Program, C Diff Foundation
Sponsored by ACURX Pharmaceuticals Clorox Healthcare
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021.
Episode 6
Group Discussion I ‘Recent Developments in Diagnosis, Treatment, and Prevention of C. difficile infections In Children.’ GROUP DISCUSSION I Thursday Afternoon Speakers Thomas J. Sandora, MD MPH (Speaker) Associate Professor of Pediatrics : PANELIST, Harvard Medical School : Panel Discussion I Larry Kociolek, MD (Speaker) Attending Physician, Ann & Robert H. Lurie Children’s Hospital Maribeth Nicholson, MD, MPH (Speaker) Assistant Professor of Pediatrics, Vanderbilt University Medical Center.
'Introduction to Microbiota and Microbiota Restoration for Recurrent C diff infections' Ken Blount, Ph.D. (Speaker) Chief Scientific Officer, Rebiotix, Inc a Ferring Company
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
Caring For a Loved One Diagnosed With a CDI
“Is this C.diff.? How IBS and IBD Complicate the Diagnosis and Management of Patients With a CDI” Caterina Oneto, MD (Speaker) Clinical Instructor, Division of Gastroenterology, NYU
“The Burden of Clostridioides difficile Infection In the COVID-19 Era” Nicola Petrosillo (Speaker) Head Infection Control and Infectious Disease Service, University Hospital Campus Bio-Medico, Rome, Italy
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 4
'Using a Gut Model to Predict Which Antibiotics Are Associated with CDI and Which Ones Best Treat CDI' Mark Wilcox, MD, FRCPath (Speaker) Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology, Leeds Teaching Hospitals
Microbiome Therapeutics in 2021: Almost there for C difficile! Sahil Khanna, MBBS MS (Speaker) Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 3
Update on the Development of Gut Microbiome Protectors from Antibiotic-Induced Dysbiosis. Florence Sejourne (Speaker) CEO, DA VOLTERRA
“Safety and Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent Clostridioides difficile Infection: A Data Summary From Five Prospective Studies” Beth Guthmueller (Speaker) Rebiotix, a Ferring Company
‘CP101, an Investigational Orally Administered Microbiome Therapeutic Designed to Prevent Recurrent CDI’ Shrish Budree (Speaker) Medical Director, Head of Clinical Microbiome Science, Finch Therapeutics
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021.
Episode 2
“The Burden of Clostridioides difficile Infection In the COVID-19 Era” Nicola Petrosillo (Speaker) Head Infection Control and Infectious Disease Service, University Hospital Campus Bio-Medico, Rome, Italy Results from ECOSPOR III, a Phase 3 Placebo-Controlled Trial of SER-109, an Investigational Microbiome Therapeutic to Reduce Recurrence of Clostridioides difficile Infection Barbara McGovern, MD (Speaker) VP, Medical Affairs, Seres Therapeutics Evidence-Based Hand Hygiene In the Post-COVID World.” Tamas Haidegger (Speaker) Associate Professor, Óbuda University ** We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 1 Paul Feuerstadt, MD, FACG, AGAF introduce the C Diff Foundation and provide an overview of a C. difficile infection. Simon M. Cutting, Ph.D. will present: What Makes Us Susceptible to a C. difficile Infection? We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
Join us with our guests from GoodNature, a Seres Therapeutics program; April Garcia, Site Manager of GoodNature Irvine California, and two GoodNature donors who will share their experiences. They will discuss the who, what, and how in donating poop to potentially support C. diff patients. With microbiome therapeutics on the forefront, it will be an educational discussion.
Join Us With our guest, Sahil Khanna, M.B.B.S., M.S. as we discuss the exciting times of Microbiome Restoration For C. difficile infections and how we are almost there! Dr. Khanna will be introducing the gut microbiome, the research, development, and importance of the microbiome in our health along with the microbiome therapeutics in clinical trials with validated safety and efficacy.
Approximately 10% of all U.S. patients report having an allergic reaction to a penicillin class antibiotic in their past. 10% of the population reports a penicillin allergy but 1% of the whole population is truly allergic. People with a penicillin allergy on their medical record are not given penicillin, and may not be given any beta-lactam antibiotics because of concern that the allergy is shared across the antibiotic class. Instead, the antibiotics prescribed may be broader-spectrum. Broad-spectrum antibiotics may be as effective, but they often have more side effects and toxicities, such as increased risk of developing infections like C. diff (Clostridioides difficile, formerly called Clostridium difficile) or methicillin-resistant Staphylococcus aureus (MRSA). Our guests Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS, Clinical Professor, University of Georgia College of Pharmacy and Bruce M. Jones, Pharm.D., BCPS, Adjunct Clinical Associate Professor for the University of Georgia College of Pharmacy will join us to discuss antibiotics, the different types, diagnostics, diagnosis, and the Impact of Penicillin Allergy on a C. difficile Infection.
Join Nancy C. Caralla and Kevin Hersh as we discuss the chapters and passion behind the newly published book, Managing a C. difficile Infection: For Patients, Families, and Caregivers.
Niranjan Tex Kissoon , MD Mark Ansermino, MD and Matthew Wiens, MD join us to discuss the multi-levels of Sepsis,. and educate us on the What, How, and Global Burden of Sepsis.
The Global Burden of Disease Sepsis Report published in January 2020 estimated that 49 million patients suffer sepsis every year, with 11 million of those dying. This burden is significantly higher than the number of lives lost to cancer or coronary disease. Sepsis can affect anyone as a consequence of infection, but globally young children suffer most. sepsis remains one of the most common and least-recognized illnesses in both the developed and developing world. Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, disability and death, especially if not recognized early and treated promptly. September has been designated Sepsis Awareness Month and September 13th is Sepsis Awareness Day. For more information please visit: https://www.global-sepsis-alliance.org and https://www.sepsis.org
Wendy Benson is partner and COO at 2x2 Health: Private Health Concierge, culminating from her extensive experience as a leading healthcare executive and occupational therapist. She is also co-author of the international best-selling book, The Confident Patient. Wendy joins us to discuss the necessity of becoming a strong health advocate and ways to manage care through unprecedented times.
Join Doctors Caterina Oneto, and Paul Feuerstadt, as they discuss the Management of C. difficile Infections. The new guidelines released by IDSA and SHEA this June along with the new treatments on the horizon will also be a topic of conversation.
Join Our Guests: Linda Davis, RN, Charlotte Johnson, & Renata Johnson as they discuss key points on caregiving, a journey of caring for a loved one with a C. diff. infection, and comparing caregiving as a profession to caring for a family member at home.
Join our guests: Neil Clark, Chief Executive Officer, Destiny Pharma PLC and Dale Gerding, MD, FACP, FIDSA, FSHEA with our Guest Host: Kevin Hersh. The robust discussion will touch upon important topics focused on the what, why, and how to Prevent CDI: Boost Immunity, Restore Microbiome, Replace the Bug. Our two guests will exchange a dialogue about the science to answer the many questions about a C. difficile infection, prevention, treatments, what is recurrent C. diff., and the immune system, and how the microbiome plays a part in everything. Tune in and expand you basic knowledge with our guests; Mr. Neil Clark and Doctor Dale Gerding.
Join us with our guest, Professor Simon Cutting, Ph. D., as we discuss the genetic control of spore formation in Bacillus subtilis, and the research behind the scenes defining Clostridioides difficile in health and environment.
Our guests from Seres Therapeutics shared the latest news on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study results were equally compelling when characterized by the alternative metric of sustained clinical response, where 88.9% of patients in the SER-109 arm achieved this objective. The study’s efficacy results exceeded the statistical threshold previously provided in consultation with the U.S. Food and Drug Administration (FDA) that could allow this single clinical study to fulfill efficacy requirements for a Biologics License Application (BLA). The SER-109 safety results were favorable, with an adverse event profile comparable to a placebo. Listen in and learn more from the leading topic experts.
Join our guests, Missy Travis, RN, and Priya Balachandran, Ph. D. COO Applied Silver, as they discuss the role of cleaning and disinfection to prevent surface contamination leading to the transmission of infections, There are also new concerns about CDI given the current state of COVID-19 and our guests will discuss this topic in great detail. What are your thoughts about linens and pathogens? Missy Travis, RN, and Dr. Balachandran will be sharing innovative solutions that maintain infection prevention in an array of settings.
Join us with our guest, Ron Roman, RN, CEO Safety Net as we discuss creating a safe environment, maintaining a safe environment in both healthcare and home. Ron will review Disinfection – what is Clean, Sanitize, Disinfect and Sterilize and how to simplify the terms.
This is a Special Presentation: Join us with our three brave guests as they take a step forward to share their C. difficile infection journey and deliver a personal message with our global listeners. It's NOT Just Diarrhea.
Join us with our guest, Professor Simon Cutting, Ph. D., as we discuss the genetic control of spore formation in Bacillus subtilis, and the research behind the scenes defining Clostridioides difficile in health and environment.
Join us with our guest, Ron Roman, RN, CEO Safety Net as we discuss creating a safe environment, maintaining a safe environment in both healthcare and home. Ron will review Disinfection – what is Clean, Sanitize, Disinfect and Sterilize and how to simplify the terms.
Metronidazole For the Treatment of C. difficile Infections: On the Way Out? - Presented by: Wiep Klaas Smits, Ph. D., Department of Medical Microbiology Leiden University Medical Center. A Four-pronged Threat: Clostridioides difficile Infection (CDI), Antibiotics, the Flu Season, and COVID-19.” - Presented by: Dr. David Lyerly, Co-founder and Chief Science Officer of TECHLAB, Inc. Aerosol Transmission of Pathogens: The Problem and the Solutions. Presented by: Maureen Spencer, RN, M.ED., CIC
Inaugural Dale Gerding Lifetime Achievement Award - Presented by Sahil Khanna, MBBS MS, Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic to Dale Gerding, MD, FACP, FIDSA. Adjunctive Therapy for CDI to Prevent Recurrence: Practical Issues. - Presented by: Dr. Dale Gerding, MD, FACP, FIDSA, Retired Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Research Physician at the Edward Hines Jr. VA Hospital. “Antimicrobial Stewardship and Its Impact On C difficile.” - Presented by: Glenn Tillotson, PHD, FIDSA, FRSM,, FCCP, FISC, Senior Consultant, Global ID, Anti-Infective Drug Development, GST Micro LLC. Metronidazole For the Treatment of C. difficile Infections: On the Way Out? - Presented by: Wiep Klaas Smits, Ph. D., Department of Medical Microbiology Leiden University Medical Center
Inaugural Dale Gerding Lifetime Achievement Award - Presented by Sahil Khanna, MBBS MS, Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic to Dale Gerding, MD, FACP, FIDSA. Adjunctive Therapy for CDI to Prevent Recurrence: Practical Issues. - Presented by: Dr. Dale Gerding, MD, FACP, FIDSA, Retired Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Research Physician at the Edward Hines Jr. VA Hospital. “Antimicrobial Stewardship and Its Impact On C difficile.” - Presented by: Glenn Tillotson, PHD, FIDSA, FRSM,, FCCP, FISC, Senior Consultant, Global ID, Anti-Infective Drug Development, GST Micro LLC. Metronidazole For the Treatment of C. difficile Infections: On the Way Out? - Presented by: Wiep Klaas Smits, Ph. D., Department of Medical Microbiology Leiden University Medical Center
“Introducing a New Disinfection Technology Against C. diff.” Jordan Bastian (Speaker) Infection Preventionist, CloroxPro Clinical and Scientific Affairs, Clorox Company
Ibezapolstat Update: Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect? Kevin Garey (Speaker) Chair of the Department of Pharmacy Practice and Translational Research and Professor of Pharmacy Practice, University of Houston College of Pharmacy
More Than a CDI: The Revolving Door and a Ray Of Hope. Kathy Bischoff (Speaker) Coordinator, VHA Program, C Diff Foundation
Sponsored by ACURX Pharmaceuticals Clorox Healthcare
We welcome our guest, Madeline King, PharmD, BCIDP Assistant Professor of Clinical Pharmacy, Infectious Diseases, Department of Pharmacy Practice & Pharmacy Administration. Dr. King joins us to discuss the updated Clostridioides difficile (C. difficile) Guidelines, along with topic of Antibiotics. Dr. King has a passion in infectious disease, public health, and truly enjoys teaching.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021.
Episode 6
Group Discussion I ‘Recent Developments in Diagnosis, Treatment, and Prevention of C. difficile infections In Children.’ GROUP DISCUSSION I Thursday Afternoon Speakers Thomas J. Sandora, MD MPH (Speaker) Associate Professor of Pediatrics : PANELIST, Harvard Medical School : Panel Discussion I Larry Kociolek, MD (Speaker) Attending Physician, Ann & Robert H. Lurie Children’s Hospital Maribeth Nicholson, MD, MPH (Speaker) Assistant Professor of Pediatrics, Vanderbilt University Medical Center.
'Introduction to Microbiota and Microbiota Restoration for Recurrent C diff infections' Ken Blount, Ph.D. (Speaker) Chief Scientific Officer, Rebiotix, Inc a Ferring Company
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021.
Episode 5
A Caregiver's Journey David Bischoff (Speaker) Co-Coordinator VHA Program, C Diff Foundation A Caregiver's Perspective ~ Caring For a Loved One Diagnosed With a CDI
“Is this C.diff.? How IBS and IBD Complicate the Diagnosis and Management of Patients With a CDI” Caterina Oneto, MD (Speaker) Clinical Instructor, Division of Gastroenterology, NYU
“The Burden of Clostridioides difficile Infection In the COVID-19 Era” Nicola Petrosillo (Speaker) Head Infection Control and Infectious Disease Service, University Hospital Campus Bio-Medico, Rome, Italy
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 4
'Using a Gut Model to Predict Which Antibiotics Are Associated with CDI and Which Ones Best Treat CDI' Mark Wilcox, MD, FRCPath (Speaker) Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology, Leeds Teaching Hospitals
Microbiome Therapeutics in 2021: Almost there for C difficile! Sahil Khanna, MBBS MS (Speaker) Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 3
Update on the Development of Gut Microbiome Protectors from Antibiotic-Induced Dysbiosis. Florence Sejourne (Speaker) CEO, DA VOLTERRA
“Safety and Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent Clostridioides difficile Infection: A Data Summary From Five Prospective Studies” Beth Guthmueller (Speaker) Rebiotix, a Ferring Company
‘CP101, an Investigational Orally Administered Microbiome Therapeutic Designed to Prevent Recurrent CDI’ Shrish Budree (Speaker) Medical Director, Head of Clinical Microbiome Science, Finch Therapeutics
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021.
Episode 2
“The Burden of Clostridioides difficile Infection In the COVID-19 Era” Nicola Petrosillo (Speaker) Head Infection Control and Infectious Disease Service, University Hospital Campus Bio-Medico, Rome, Italy Results from ECOSPOR III, a Phase 3 Placebo-Controlled Trial of SER-109, an Investigational Microbiome Therapeutic to Reduce Recurrence of Clostridioides difficile Infection Barbara McGovern, MD (Speaker) VP, Medical Affairs, Seres Therapeutics Evidence-Based Hand Hygiene In the Post-COVID World.” Tamas Haidegger (Speaker) Associate Professor, Óbuda University ** We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 1 Paul Feuerstadt, MD, FACG, AGAF introduce the C Diff Foundation and provide an overview of a C. difficile infection. Simon M. Cutting, Ph.D. will present: What Makes Us Susceptible to a C. difficile Infection? We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
Join us with our guest; Ken Blount PhD, CSO Rebiotix Inc, a Ferring Company and VP Microbiome Research Ferring - as Dr. Blount introduces the gut microbiome. There is so much to learn about this cutting edge science, along with a discussion about the recurrence of a C. difficile infection , and how clinical trials work.. The gut microbiome has a direct connection to our health and Dr. Blount will be shining some light on this educational topic Have your mobile devices or a pen and notebook ready as we learn more about the gut microbiome, C. difficile infections, clinical trials, and much more!
Nancy C. Caralla and Kevin Hersh as we discuss the chapters and passion behind the newly published book, Managing a C. difficile Infection: For Patients, Families, and Caregivers.
Join Us With our guest, Sahil Khanna, M.B.B.S., M.S. as we discuss the exciting times of Microbiome Restoration For C. difficile infections and how we are almost there! Dr. Khanna will be introducing the gut microbiome, the research, development, and importance of the microbiome in our health along with the microbiome therapeutics in clinical trials with validated safety and efficacy.
Doctors Caterina Oneto, and Paul Feuerstadt discussed the Management of C. difficile Infections. The new guidelines released by IDSA and SHEA this June along with the new treatments on the horizon were also a topic of conversation.
Approximately 10% of all U.S. patients report having an allergic reaction to a penicillin class antibiotic in their past. 10% of the population reports a penicillin allergy but 1% of the whole population is truly allergic. People with a penicillin allergy on their medical record are not given penicillin, and may not be given any beta-lactam antibiotics because of concern that the allergy is shared across the antibiotic class. Instead, the antibiotics prescribed may be broader-spectrum. Broad-spectrum antibiotics may be as effective, but they often have more side effects and toxicities, such as increased risk of developing infections like C. diff (Clostridioides difficile, formerly called Clostridium difficile) or methicillin-resistant Staphylococcus aureus (MRSA). Our guests Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS, Clinical Professor, University of Georgia College of Pharmacy and Bruce M. Jones, Pharm.D., BCPS, Adjunct Clinical Associate Professor for the University of Georgia College of Pharmacy will join us to discuss antibiotics, the different types, diagnostics, diagnosis, and the Impact of Penicillin Allergy on a C. difficile Infection.
Join us with our guests from GoodNature, a Seres Therapeutics program; April Garcia, Site Manager of GoodNature Irvine California, and two GoodNature donors who will share their experiences. They will discuss the who, what, and how in donating poop to potentially support C. diff patients. With microbiome therapeutics on the forefront, it will be an educational discussion.
Join Us With our guest, Sahil Khanna, M.B.B.S., M.S. as we discuss the exciting times of Microbiome Restoration For C. difficile infections and how we are almost there! Dr. Khanna will be introducing the gut microbiome, the research, development, and importance of the microbiome in our health along with the microbiome therapeutics in clinical trials with validated safety and efficacy.
Join us with our guest; Ken Blount PhD, CSO Rebiotix Inc, a Ferring Company and VP Microbiome Research Ferring - as Dr. Blount introduces the gut microbiome. There is so much to learn about this cutting edge science, along with a discussion about the recurrence of a C. difficile infection , and how clinical trials work.. The gut microbiome has a direct connection to our health and Dr. Blount will be shining some light on this educational topic
Have your mobile devices or a pen and notebook ready as we learn more about the gut microbiome, C. difficile infections, clinical trials, and much more!
Approximately 10% of all U.S. patients report having an allergic reaction to a penicillin class antibiotic in their past. 10% of the population reports a penicillin allergy but 1% of the whole population is truly allergic. People with a penicillin allergy on their medical record are not given penicillin, and may not be given any beta-lactam antibiotics because of concern that the allergy is shared across the antibiotic class. Instead, the antibiotics prescribed may be broader-spectrum. Broad-spectrum antibiotics may be as effective, but they often have more side effects and toxicities, such as increased risk of developing infections like C. diff (Clostridioides difficile, formerly called Clostridium difficile) or methicillin-resistant Staphylococcus aureus (MRSA). Our guests Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS, Clinical Professor, University of Georgia College of Pharmacy and Bruce M. Jones, Pharm.D., BCPS, Adjunct Clinical Associate Professor for the University of Georgia College of Pharmacy will join us to discuss antibiotics, the different types, diagnostics, diagnosis, and the Impact of Penicillin Allergy on a C. difficile Infection.
With microbiome therapeutics on the forefront, it will be an educational discussion with our guests: Jason Goldsmith, Donor Medical & Analytical Sciences, Elisha Ott, Director, Donor Operations, and Jennie Starr, Associate Director, Donor Recruitment.
Each guest will be sharing the information about the donor process, and the who, what, and how in donating poop for a good cause.
Niranjan Tex Kissoon , MD Mark Ansermino, MD and Matthew Wiens, MD join us to discuss the multi-levels of Sepsis,. and educate us on the What, How, and Global Burden of Sepsis.
The Global Burden of Disease Sepsis Report published in January 2020 estimated that 49 million patients suffer sepsis every year, with 11 million of those dying. This burden is significantly higher than the number of lives lost to cancer or coronary disease. Sepsis can affect anyone as a consequence of infection, but globally young children suffer most. sepsis remains one of the most common and least-recognized illnesses in both the developed and developing world. Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, disability and death, especially if not recognized early and treated promptly. September has been designated Sepsis Awareness Month and September 13th is Sepsis Awareness Day. For more information please visit: https://www.global-sepsis-alliance.org and https://www.sepsis.org
Join Nancy C. Caralla and Kevin Hersh as we discuss the chapters and passion behind the newly published book, Managing a C. difficile Infection: For Patients, Families, and Caregivers.
Niranjan Tex Kissoon , MD Mark Ansermino, MD and Matthew Wiens, MD join us to discuss the multi-levels of Sepsis,. and educate us on the What, How, and Global Burden of Sepsis.
The Global Burden of Disease Sepsis Report published in January 2020 estimated that 49 million patients suffer sepsis every year, with 11 million of those dying. This burden is significantly higher than the number of lives lost to cancer or coronary disease. Sepsis can affect anyone as a consequence of infection, but globally young children suffer most. sepsis remains one of the most common and least-recognized illnesses in both the developed and developing world. Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, disability and death, especially if not recognized early and treated promptly. September has been designated Sepsis Awareness Month and September 13th is Sepsis Awareness Day. For more information please visit: https://www.global-sepsis-alliance.org and https://www.sepsis.org
Wendy Benson is partner and COO at 2x2 Health: Private Health Concierge, culminating from her extensive experience as a leading healthcare executive and occupational therapist. She is also co-author of the international best-selling book, The Confident Patient. Wendy joins us to discuss the necessity of becoming a strong health advocate and ways to manage care through unprecedented times.
Wendy Benson is partner and COO at 2x2 Health: Private Health Concierge, culminating from her extensive experience as a leading healthcare executive and occupational therapist. She is also co-author of the international best-selling book, The Confident Patient. Wendy joins us to discuss the necessity of becoming a strong health advocate and ways to manage care through unprecedented times.
Dr. Tamas Haidegger, Ph. D., Associate Professor Obuda University, and Co-founder: HandInscan will be discussing the importance of not only hand-washing but how Hand Hygiene is the top priority in social safety. Hand Hygiene remains the number one infection prevention action individuals can utilize worldwide to prevent the spread of germs and viruses worldwide. Dr. Haidegger will also introduce the research and science behind the HandInScan - an objective hand hygiene control in the medical environment.
Doctors Caterina Oneto, and Paul Feuerstadt discussed the Management of C. difficile Infections. The new guidelines released by IDSA and SHEA this June along with the new treatments on the horizon were also a topic of conversation.
Join Doctors Caterina Oneto, and Paul Feuerstadt, as they discuss the Management of C. difficile Infections. The new guidelines released by IDSA and SHEA this June along with the new treatments on the horizon will also be a topic of conversation.
Join Our Guests: Linda Davis, RN, Charlotte Johnson, & Renata Johnson as they discuss key points on caregiving, a journey of caring for a loved one with a C. diff. infection, and comparing caregiving as a profession to caring for a family member at home.
Join Our Guests: Linda Davis, RN, Charlotte Johnson, & Renata Johnson as they discuss key points on caregiving, a journey of caring for a loved one with a C. diff. infection, and comparing caregiving as a profession to caring for a family member at home.
With microbiome therapeutics on the forefront, it will be an educational discussion with our guests: Jason Goldsmith, Donor Medical & Analytical Sciences, Elisha Ott, Director, Donor Operations, and Jennie Starr, Associate Director, Donor Recruitment.
Each guest will be sharing the information about the donor process, and the who, what, and how in donating poop for a good cause.
Join our guests: Neil Clark, Chief Executive Officer, Destiny Pharma PLC and Dale Gerding, MD, FACP, FIDSA, FSHEA with our Guest Host: Kevin Hersh. The robust discussion will touch upon important topics focused on the what, why, and how to Prevent CDI: Boost Immunity, Restore Microbiome, Replace the Bug. Our two guests will exchange a dialogue about the science to answer the many questions about a C. difficile infection, prevention, treatments, what is recurrent C. diff., and the immune system, and how the microbiome plays a part in everything. Tune in and expand you basic knowledge with our guests; Mr. Neil Clark and Doctor Dale Gerding.
Join our guests: Neil Clark, Chief Executive Officer, Destiny Pharma PLC and Dale Gerding, MD, FACP, FIDSA, FSHEA with our Guest Host: Kevin Hersh. The robust discussion will touch upon important topics focused on the what, why, and how to Prevent CDI: Boost Immunity, Restore Microbiome, Replace the Bug. Our two guests will exchange a dialogue about the science to answer the many questions about a C. difficile infection, prevention, treatments, what is recurrent C. diff., and the immune system, and how the microbiome plays a part in everything. Tune in and expand you basic knowledge with our guests; Mr. Neil Clark and Doctor Dale Gerding.
This is a Special Presentation: Join us with our three brave guests as they take a step forward to share their C. difficile infection journey and deliver a personal message with our global listeners. It's NOT Just Diarrhea.
Join us with our guest, Professor Simon Cutting, Ph. D., as we discuss the genetic control of spore formation in Bacillus subtilis, and the research behind the scenes defining Clostridioides difficile in health and environment.
Our guests from Seres Therapeutics shared the latest news on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study results were equally compelling when characterized by the alternative metric of sustained clinical response, where 88.9% of patients in the SER-109 arm achieved this objective. The study’s efficacy results exceeded the statistical threshold previously provided in consultation with the U.S. Food and Drug Administration (FDA) that could allow this single clinical study to fulfill efficacy requirements for a Biologics License Application (BLA). The SER-109 safety results were favorable, with an adverse event profile comparable to a placebo. Listen in and learn more from the leading topic experts.
Join our guests, Missy Travis, RN, and Priya Balachandran, Ph. D. COO Applied Silver, as they discuss the role of cleaning and disinfection to prevent surface contamination leading to the transmission of infections, There are also new concerns about CDI given the current state of COVID-19 and our guests will discuss this topic in great detail. What are your thoughts about linens and pathogens? Missy Travis, RN, and Dr. Balachandran will be sharing innovative solutions that maintain infection prevention in an array of settings.
Join our guests, Missy Travis, RN, and Priya Balachandran, Ph. D. COO Applied Silver, as they discuss the role of cleaning and disinfection to prevent surface contamination leading to the transmission of infections, There are also new concerns about CDI given the current state of COVID-19 and our guests will discuss this topic in great detail. What are your thoughts about linens and pathogens? Missy Travis, RN, and Dr. Balachandran will be sharing innovative solutions that maintain infection prevention in an array of settings.
Join us with our guest, Ron Roman, RN, CEO Safety Net as we discuss creating a safe environment, maintaining a safe environment in both healthcare and home. Ron will review Disinfection – what is Clean, Sanitize, Disinfect and Sterilize and how to simplify the terms.
Join us with our guest, Ron Roman, RN, CEO Safety Net as we discuss creating a safe environment, maintaining a safe environment in both healthcare and home. Ron will review Disinfection – what is Clean, Sanitize, Disinfect and Sterilize and how to simplify the terms.
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
This is a Special Presentation: Join us with our three brave guests as they take a step forward to share their C. difficile infection journey and deliver a personal message with our global listeners. It's NOT Just Diarrhea.
Join us with our guest James Boone, M.S., as we discuss Inflammatory Bowel Disease patients who are highly susceptible to C. difficile infections. The two diseases have similar symptoms, but very different treatments. This segment will examine the diagnostic methods which can distinguish between inflammatory bowel disease and C. difficile infection, discuss testing guidelines, and touch upon recent clinical research and advances.
Join us with our guest, Professor Simon Cutting, Ph. D., as we discuss the genetic control of spore formation in Bacillus subtilis, and the research behind the scenes defining Clostridioides difficile in health and environment.
Join us with our guest, Ron Roman, RN, CEO Safety Net as we discuss creating a safe environment, maintaining a safe environment in both healthcare and home. Ron will review Disinfection – what is Clean, Sanitize, Disinfect and Sterilize and how to simplify the terms.
Join us with our guest, Ron Roman, RN, CEO Safety Net as we discuss creating a safe environment, maintaining a safe environment in both healthcare and home. Ron will review Disinfection – what is Clean, Sanitize, Disinfect and Sterilize and how to simplify the terms.
Our two guests, Teena Chopra, MD, MPH and Glenn Tillitson, PhD,FIDSA, will be discussing how C. diff. infections correlate with COVID-19 and how the pandemic not only provides lessons about the judicious use of antibiotics, but it also highlights another global health threat that has been playing out in slow motion: the mounting threat of antimicrobial resistance that annually claims 700,000 lives as the world’s arsenal of antibiotics and antifungal medication lose their ability to vanquish dangerous pathogens. There will be discussions focused on studies, and what may be the epidemiological impact of COVID/CDI in post hospital care and much more.
Join us with three C. diff. Survivors - Christine, Alba, and Renata, as they share their personal message with you.
We are grateful for their time and for sharing their C. diff. infection experiences with us.
Join us with three C. diff. Survivors - Christine, Alba, and Renata, as they share their personal message with you.
We are grateful for their time and for sharing their C. diff. infection experiences with us.
Join Our Guests Camilla Graham MD Ri-CoDIFy: Ridinilazole’s Phase 3 Trial for the Treatment of C. difficile and Reduction of Recurrence. . Dr.Camilla S. Graham is Vice President and Chief Clinical Information Officer at Summit Therapeutics as well as a staff physician at Beth Israel Deaconess Medical Center in Boston, MA, and on faculty at Harvard Medical School. Guest: Alba Muhlfeld, C. diff. Survivor - Sharing her C. diff. infection journey. Guest: Erik Dubburke, MD, MSPH discusses “Optimizing Prevention of Hospital-Onset Clostridioides difficile infection.” Dr. Erik Dubberke is an Associate Professor of Medicine at Washington University School of Medicine in St. Louis, where he has been a faculty member in the Division of Infectious Diseases since 2005. He is an Associate Hospital Epidemiologist at Barnes-Jewish Hospital, Presentations delivered live during the November 14th, 2020 8th Annual International C. diff. Conference & Health EXPO
A Symposium specifically developed for Patients Diagnosed With a C. diff. Infection, Being Treated For a Clostridioides diffiicile infection, Recovering From a Clostridioides difficile Infection and Recurrences with Family Members and Caregivers. Distinguished members and keynote speakers provide insight as to what impacts the patient and families on both quality and economic topics, what role leadership plays in creating the right culture for patient-centered care, and how to identify, evaluate, and prioritize innovations that can quickly touch the lives of patients battling C. diff. infections.
Kathy Bischoff, C. diff. Survivor My C. diff. Journey
Renata Johnson, C. diff. Survivor My C. diff. Journey
Paul Feuerstadt, MD - review
Barbara McGovern, MD, “Treatment of recurrent C. difficile infection with SER-109, an investigational microbiome drug.
A Symposium specifically developed for Patients Diagnosed With a C. diff. Infection, Being Treated For a Clostridioides diffiicile infection, Recovering From a Clostridioides difficile Infection and Recurrences with Family Members and Caregivers. Distinguished members and keynote speakers provide insight as to what impacts the patient and families on both quality and economic topics, what role leadership plays in creating the right culture for patient-centered care, and how to identify, evaluate, and prioritize innovations that can quickly touch the lives of patients battling C. diff. infections.
Courtney Jones ” Microbiome, Microbiota, and Gut Health.” Denise Cardo, MD “Everyone Has a Role in Antibiotic Awareness.” Larry Kociolek, MD “C. diff. Infections in Pediatrics.”
This event was sponsored by Seres Therapeutics. Seres Therapeutics mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics
Enjoy the program!
Welcome to the second episode of a special four (4) part series: A Symposium Created For Patients Diagnosed With a C. diff. Infection, Being Treated For a Clostridioides diffiicile infection, Recovering From a Clostridioides difficile Infection and Recurrences with Family Members and Caregivers. Welcome to a Symposium specifically developed for patients, families, and caregivers. The Patient & Family C. diff. Symposium: where a gathering of healthcare professionals, keynote speakers, health advocates, practitioners, educators, are transforming the patient experience, and changing the way people experience C. diff. infections worldwide. Simon Cutting, Ph. D. “Bacillus, and C. diff. Spore Overview. “ Teena Chopra, MD ” Introduction to Infection Prevention.” Doe Kley, RN, MPH “C. diff. Transitioning from Hospital to Home. This event was sponsored by Seres Therapeutics, Seres Therapeutic's mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics Enjoy the presentations by the topic leaders joining us!
The Patient & Family C. diff. Symposium: A gathering of healthcare professionals, keynote speakers, health advocates, practitioners, educators, thought leaders, and patients who are transforming the patient experience, and changing the way people experience C. diff. infections worldwide.
Program Presenter: Paul Feuerstadt, MD, FACG
Barbara McGovern, MD “Treatment of recurrent C. difficile infection with SER-109, an investigational microbiome drug.” Paul Feuerstadt, MD ” C. diff. Overview – What is a C. diff. Infection?” Sahil Khanna, MBBS, “C. diff. Treatments and FMT Overview. “
Join us with our guests Elizabeth A.Myers, BSN, RN, and Wendy Benson, MBA, OTR/L as we discuss the challenges of today's healthcare and their published book, The Confident Patient which answers the many questions and guides patients and families through the healthcare mazes. Have your tablets, pen, and paper ready to jot down notes as we discuss healthcare solutions and helpful information for the entire family to expand everyone's advocacy skills
Join us with our guests; With Doctor Teena Chopra, MD,MPH,FACP,FIDSA,FSHEA Associate Professor of Medicine,Division of Infectious Diseases, Corporate Medical Director, Infection Prevention,Epidemiology,and Antibiotic Stewardship ,DMC and WSU Director,Infection Prevention,Epidemiology and Antibiotic Stewardship,Vibra Hospital
Dr. Chopra will lead the discussion with an overview of a C. difficile infection followed by Alba Muhlfeld, and Renata Johnson, C. diff. Survivors both sharing their journey and providing key-points to our global listeners.
Join us with our guests from Seres Therapeutics as they discuss the latest news on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study results were equally compelling when characterized by the alternative metric of sustained clinical response, where 88.9% of patients in the SER-109 arm achieved this objective. The study’s efficacy results exceeded the statistical threshold previously provided in consultation with the U.S. Food and Drug Administration (FDA) that could allow this single clinical study to fulfill efficacy requirements for a Biologics License Application (BLA). The SER-109 safety results were favorable, with an adverse event profile comparable to placebo. Listen in and learn more from the leading topic experts.
Dr. Tamas Haidegger, Ph. D., Associate Professor Obuda University, and Co-founder: HandInscan will be discussing the importance of not only hand-washing but how Hand Hygiene is the top priority in social safety. Hand Hygiene remains the number one infection prevention action individuals can utilize worldwide to prevent the spread of germs and viruses worldwide. Dr. Haidegger will also introduce the research and science behind the HandInScan - an objective hand hygiene control in the medical environment.
Join us with our guest Dr. Robert Carman, Ph. D., Director of Microbiology at TECHLAB, Inc. Dr. Carman's research focuses on Clostridioides difficile (C. diff., C. difficile, CDI). Dr. Carman not only introduces us to the gut microbiome, but explains the details of the environment, the colonies of microorganisms, bacteria, viruses, protozoa, and fungi, that are present in the gastrointestinal tract
Join us with Guest; Doe Kley, RN, CIC, MPH,T-CHEST Senior Infection Preventionist with Clorox Professional Products Co. Ms. Kley will be discussing the importance of knowing the key-points in transitioning from an acute-care facility, long-term facility, and intermediate healthcare facility to the home environment.
Join us with Guest; Doe Kley, RN, CIC, MPH,T-CHEST Senior Infection Preventionist with Clorox Professional Products Co. Ms. Kley will be discussing the importance of knowing the key-points in transitioning from an acute-care facility, long-term facility, and intermediate healthcare facility to the home environment.
Join us with our guest: Candida Fratazzi, MD, Consulting Medical Director at Vedanta Biosciences, focused on pioneering rational design of drugs, made of defined consortia of bacteria, to Modulate the Human Microbiome. Dr. Fratazzi will be discussing and explaining Microbiome functions and how its changes impact our health. How bacteria colonies’ equilibrium is supported and supports our immune system. Thus, the need to correct imbalance of bacteria colonies not with untargeted pull of bacteria such as fecal transplant or with a single strain of bacteria such as probiotics. Dr Fratazzi will certainly be educating us on this episode, Why Bacterial Consortia May Stop C. diff. Recurrences”
Welcome to Episode 6 of 6; of the 8th Annual International C. diff. Post-Conference Special series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics while focusing on the leading HAI - Clostridioides difficile We will hear from the following keynote speakers:
Camilla S. Graham, MD, MPH, Ri-Co-DIFy: Summit's Ridinilazole Phase 3 Trial to Advance the Sciences in the Treatment of C. difficile and Reduction of Recurrence. Maureen Spencer, RN, M.Ed., CIC, Engaging Middle School Children In Infection Prevention Through the C Diff Foundation's Junior Infection Fighters Program. Alba Muhlfeld, C. diff. Survivor, Patient's Journey. Erik Dubberke, MD, MSPH, Optimizing Prevention of Hospital-Onset Clostridioides difficile Infection.
Many of the presentation slides are available to view/download until January 14th, 2021 located on the dedicated conference website: www.cdiff2020.com
Welcome to Episode 5 of 6; of the 8th Annual International C. diff. Post-Conference special series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics as in leading annual collaborative events while focusing on Healthcare-associated infections (HAI), and the leading HAI -- Clostridioides difficile (Also known as C. diff., C. difficile, CDI, CDAD). We will hear from the following keynote speakers
Barbara McGovern, MD, ECOSPORIII: A Phase 3 Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of SER-109, an Investigational Microbiome Therapeutic for the Treatment of Patients w/Recurrent Clostridioides difficile Infection (rCDI). Glenn Tillotson, Ph.D., FRSM, FCCP, It's a Small World w/C. diff. - a One Health Perspective. Dayle Skelly, C. diff. Survivor, A Patient's Journey.
Many of the presentation Slides are available until January 14th, 2021 on www.cdiff2020.com We hope you enjoy the presentations.
Welcome to Episode 4 of 6; of the 8th Annual International C. diff. Post-Conference special series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics as in leading annual, collaborative events while focusing on Healthcare-associated infections (HAI), and the leading HAI -- Clostridioides difficile (Also known as C. diff., C. difficile, CDI, CDAD). We will hear from three leading topic-experts:
Mark Wilcox, MD, FRCPath, DNA Fingerprinting to Understand C. difficile Transmission in Hospitals. Caterina Oneto, MD, Patient Support; In-Person, and Through the Global TeleSupport Network. Sahil Khanna, MBBS, MD, Microbiome Restoration; Getting One Step Closer Every Day!
Many of the presentation Slides are available until January 14th, 2021 on www.cdiff2020.com We hope you enjoy the presentations from the leading speakers of the 8th Annual Int'l C. diff. Conference & Health EXPO. This audio broadcast is sponsored by Summit Therapeutics
Welcome to Episode 3 of 6; of the 8th Annual Int'l C. diff. Post-Conference special series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics as in leading annual, collaborative events while focusing on Healthcare-associated infections (HAI), and the leading HAI -- Clostridioides difficile (Also known as C. diff., C. difficile, CDI, CDAD) with interconnected topics. In this episode, we will hear from three leading topic-experts: Teena Chopra, MD, Introduction to Infection Prevention. David Lyerly, Ph. D., Clostridioides difficile Infection; An Inflammatory Intestinal Disease. Dale Gerding, MD, FACP, FIDSA, Non-toxigenic C. difficile Is Back,.
Presentation Slides are available until January 14th, 2021 on www.cdiff2020.com We hope you enjoy the presentations from the leading topic-experts ,key note speakers of the 8th Annual Int'l C. diff. Conference & Health EXPO. This audio broadcast is sponsored by Summit Therapeutics www.summitplc.com
Welcome to Episode 2 of 6; of the 8th Annual Int'l C. diff. Post-Conference Special series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics as in leading annual, collaborative events while focusing on Healthcare-associated infections (HAI), and the leading HAI -- Clostridioides difficile (Also known as C. diff., C. difficile, CDI, CDAD) with interconnected topics. In this episode, we will hear from two leading topic-experts and one C. diff. Survivor: Dayle Skelly, C. diff. Survivor A Patient's Journey. Dr. L. Clifford McDonald, MD: Update from the Center for Disease Control and Prevention. Dr. Erik Dubberke, MD, MSPH: Optimizing Prevention of Hospital-Onset Clostridioides difficile.
Presentation Slides are available until January 14th, 2021 on www.cdiff2020.com We hope you enjoy the presentations from the 8th Annual Int'l C. diff. Conference & Health EXPO. This audio broadcast is sponsored by Summit Therapeutics www.summitplc.com
Welcome to Episode 1 of 6; 8th Annual Int'l C. diff. Post-Conference Special Series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics as in leading annual, collaborative event possessed while focusing on Healthcare-associated infections (HAI), and a leading HAI -- Clostridioides difficile (Also known as C. diff., C. difficile, CDI, CDAD) with interconnected topics. In this episode, we will hear from two leading topic-expert, and one C. diff. Survivor: Dr. Paul Feuerstadt C. difficile Infection; Foundation For the Conference. Mrs. Courtney Jones, Developing Next-Generation Microbioe-Based Therapeutics. and Alba Muhlfield, C. diff. Survivor ~ A Patient's Journey.
Presentation Slides are available until January 14th, 2021 on www.cdiff2020.com
We hope you enjoy the presentations from the 8th Annual International C. diff. Conference & Health EXPO. This audio broadcast is sponsored by Summit Therapeutics www.summitplc.com
This episode of “C. diff. Spores and More” is focused on What is IBS? So you've been diagnosed with IBS (Irritable Bowel Sydrome). Now what? Join us for a discussion about the definition, diagnosis, and treatment of the various forms of IBS with our special guests: Dr. Caterina Oneto,, MD and Dr. Paul Feuerstadt, MD, Both professors and physicians specializing in Gastroenterology with a wealth of knowledge and experience treating patients diagnosed with a CDI and through ongoing scientific/medical research.
Join us with our guest: Mrs. Courtney Jones, Upstream Marketing Manager and Senior Project Manager at Rebiotix, a Ferring Pharmaceuticals company, focused on harnessing the power of the human microbiome to treat debilitating diseases. Mrs. Jones will be discussing and explaining the Microbiome. What Microbes are and the difference between the good, bad, and in between and what the Microbiome has to do with C.diff. treatment. There is a lot to learn about the science of the Microbiome and Mrs. Jones will certainly be educating us on this episode, Researching Bugs as Drugs to Fight C.diff..
Join us with our guests: Layla and Emma, members of a group of students, also known as the Golden Pandas, an FLL Robotics Team from Westfield, IN who has developed a special interest in helping to fight C. diff. infections.
You can learn more this group of young researchers and reach out to the team on their YouTube Channel: https://www.youtube.com/watch?v=rKs_GiYjdN4
Join our guests Andrew Rushworth and Mike Short as they discuss essential tools in an infection control program. Microfiber cloths and mops provide superior microbe and organic matter removal compared to traditional textiles but not all microfiber is created equal. Hear about what sets quality microfiber apart, the evidence behind it, and how it can serve as an effective infection prevention solution in healthcare.
Dr. David M. Lyerly, Ph. D., Chief Science Officer, TechLab, Inc. will be joining us to discuss C. difficile Infections (CDI) and Secondary Bacterial Pneumonia. Dr. Lyerly will lead us off in an overview of viral respiratory infections and how they can lead to secondary bacterial pneumonia. As a result, antibiotics often are given empirically to prevent these types of secondary infections. Treatment with antibiotics, although justified in the treatment of bacterial pneumonia, is a primary predisposing factor in the onset of C. difficile infections (CDI). This discussion will provide a background on CDI and secondary bacterial pneumonia. The discussion will also include the relationship between viral and bacterial pneumonia, and how they relate to the onset of a CDI. In addition, the challenge of accurately identifying COVID-19 and FLU season will be discussed. Concluding remarks will focus on why antibiotic stewardship remains especially critical during this global pandemic.
Join us with our guest James Boone, M.S., as we discuss Inflammatory Bowel Disease patients who are highly susceptible to C. difficile infections. The two diseases have similar symptoms, but very different treatments. This segment will examine the diagnostic methods which can distinguish between inflammatory bowel disease and C. difficile infection, discuss testing guidelines, and touch upon recent clinical research and advances.
Join us with Guest; Doe Kley, RN, CIC, MPH,T-CHEST Senior Infection Preventionist with Clorox Professional Products Co. Ms. Kley will be discussing the importance of knowing the key-points in transitioning from an acute-care facility, long-term facility, and intermediate healthcare facility to the home environment.
Join our guests, Paul Feuerstadt, MD, FACG, and Mena Boules, MD join us to discuss Esophagitis and Chronic Idiopathic Constipation. Eosinophilic gastroenteritis (EGE) represents one member within the spectrum of diseases collectively referred to as eosinophilic gastrointestinal disorders (EGIDs), which includes eosinophilic esophagitis (EoE), gastritis, enteritis, and colitis. Doctors Feuerstadt and Boules will discuss how some patients present with EGID limited to the stomach (eosinophilic gastritis, EG) or duodenum (eosinophilic duodenitis, ED, EoE, and EGE are closely related disease entities. Our guest Physicians will discuss the diagnosis of Esophagitis, EGE, EoE, Chronic Idiopathic Constipation treatments, and the management of these Digestive Health topics.
Join us with our two guests: Edmond A. Hooker, MD, DrPH, and Bruce Rippe, CEO Trinity Guardion as we discuss the Three Cleaning and Disinfection Mistakes that Put Patients At Risk Both Dr. Hooker and Bruce Rippe concentrate on patient safety and infection prevention in the healthcare industry. Trinity Guardion is a recipient of the C Diff Foundation's Infection Prevention Making a Difference Award. Their dedication focuses and elevates the importance of patient safety by raising the bar through the research and education on hospital/healthcare patient bed mattresses. The clinically proven hospital bed protection barrier prevents the spreading of infections. The Trinity Guardion organization is a leading trailblazer in patient safety and proven reductions in Healthcare-associated infections (HAI's) especially C. difficile infections. Tune in as we discuss HAI's, Disinfecting, Patient Safety, and the cleaning/disinfection mistakes that put patients at risk.
Join us with our guest, Barbara DeBaun, RN, MSN, CIC. Barbara DeBaun has over 40 years of experience in the field of infection prevention and quality improvement. We will be discussing Better Blood Culture Tests Equal Better Patient Care, Fewer Antibiotics, and Less New Diagnosis of C. difficile. Barbara DeBaun will be providing key points on Laboratory Stewardship, Blood Culture gold standards, Venipuncture Technique to reduce contamination, Peer-Reviewed studies and the technology being used outside of venipuncture. Proper technique, reducing contaminated blood cultures, increase accurate results, equals better patient care, fewer antibiotics, resulting in fewer newly diagnosed cases of a C. difficile infection.
Join us with our guests from Seres Therapeutics as they discuss the latest news on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study results were equally compelling when characterized by the alternative metric of sustained clinical response, where 88.9% of patients in the SER-109 arm achieved this objective. The study’s efficacy results exceeded the statistical threshold previously provided in consultation with the U.S. Food and Drug Administration (FDA) that could allow this single clinical study to fulfill efficacy requirements for a Biologics License Application (BLA). The SER-109 safety results were favorable, with an adverse event profile comparable to placebo. Listen in and learn more from the leading topic experts.
Join us with our guest, Dr. Anthony Gerlach, PharmD, as we discuss the role of the pharmacist focusing on clinical pharmacist or rounding pharmacist. He will also discuss how clinical pharmacists are involved in the treatment and prevention of C. diff. infections.
Join us with our guest, Dr. Anthony Gerlach, PharmD, as we discuss the role of the pharmacist focusing on clinical pharmacist or rounding pharmacist. He will also discuss how clinical pharmacists are involved in the treatment and prevention of C. diff. infections.
Join us with Guest; Mrs. Courtney Jones as we discuss we can cover the microbiome & C. diff (my area of knowledge), the importance of clinical trials in general, and how we as an industry are navigating the pandemic as other diseases don’t just “wait” for it to be over. Courtney will be discussing the human gut microbiome along with the C. diff. infection, recurrences, and major topics of both. Bring your tablet and prepare to take notes on these important topics.
Join us with Guest; Mrs. Courtney Jones as we discuss we can cover the microbiome & C. diff (my area of knowledge), the importance of clinical trials in general, and how we as an industry are navigating the pandemic as other diseases don’t just “wait” for it to be over. Courtney will be discussing the human gut microbiome along with the C. diff. infection, recurrences, and major topics of both. Bring your tablet and prepare to take notes on these important topics.
Join us with our guests from Seres Therapeutics as they discuss the latest news on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study results were equally compelling when characterized by the alternative metric of sustained clinical response, where 88.9% of patients in the SER-109 arm achieved this objective. The study’s efficacy results exceeded the statistical threshold previously provided in consultation with the U.S. Food and Drug Administration (FDA) that could allow this single clinical study to fulfill efficacy requirements for a Biologics License Application (BLA). The SER-109 safety results were favorable, with an adverse event profile comparable to placebo. Listen in and learn more from the leading topic experts.
Join us with our Host, Nancy Caralla and our special Guest Host, Kevin Hersh, International Health Coach who will discuss ways to move forward past a long-term illness, and a long-term negative mind-set. Taking a moment to reflect, step back, evaluate, and look for the assets and positives in moving forward. Learn how to let the past go and embrace the new opportunities each day delivers. It takes strength, will, and the determination to step into the light and out of the darkness of the illness that paralyzes a healthy individual. Join us and take a step in a new direction.
Join us with our guest: Candida Fratazzi, MD, Consulting Medical Director at Vedanta Biosciences, focused on pioneering rational design of drugs, made of defined consortia of bacteria, to Modulate the Human Microbiome. Dr. Fratazzi will be discussing and explaining Microbiome functions and how its changes impact our health. How bacteria colonies’ equilibrium is supported and supports our immune system. Thus, the need to correct imbalance of bacteria colonies not with untargeted pull of bacteria such as fecal transplant or with a single strain of bacteria such as probiotics. Dr Fratazzi will certainly be educating us on this episode, Why Bacterial Consortia May Stop C. diff. Recurrences”
Join us with Guest; Doe Kley, RN, CIC, MPH,T-CHEST Senior Infection Preventionist with Clorox Professional Products Co. Ms. Kley will be discussing the importance of knowing the key-points in transitioning from an acute-care facility, long-term facility, and intermediate healthcare facility to the home environment.
Join us with Guest; Doe Kley, RN, CIC, MPH,T-CHEST Senior Infection Preventionist with Clorox Professional Products Co. Ms. Kley will be discussing the importance of knowing the key-points in transitioning from an acute-care facility, long-term facility, and intermediate healthcare facility to the home environment.
Join us with our Guest; Dale N. Gerding, MD, MACP, FIDSA, FSHEA. Dr. Gerding is a Research Physician at the Edward Hines Jr. VA Hospital and Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois (retired). Dr. Gerding's long and distinguished career includes past president of the Society for Healthcare Epidemiology of America, past chair of the antibiotic resistance committee of SHEA and past chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA. He was the recipient of the 2013 William S. Middleton Award. The Middleton Award is the highest honor awarded annually by the Biomedical Laboratory Research and Development Service to senior VA biomedical research scientists.
Dr. Gerding will be discussing C. diff. as a bacterium, the infection on the Epidemiology level in prevention, treatments, with the research and development of Clinical Trials. This super bug history is a stellar beginning
Join us with our guest: Ms. Courtney Jones, Upstream Marketing Manager and Senior Project Manager at Rebiotix, a Ferring Pharmaceuticals company, focused on harnessing the power of the human microbiome to treat debilitating diseases. Ms. Jones will be discussing and explaining the Microbiome. What Microbes are and the difference between the good, bad, and in between and what the Microbiome has to do with C.diff. treatment. There is a lot to learn about the science of the Microbiome and Ms. Jones will certainly be educating us on this episode, Researching Bugs as Drugs to Fight C.diff..
Our two guests, Teena Chopra, MD, MPH and Glenn Tillitson, PhD,FIDSA, will be discussing how C. diff. infections correlate with COVID-19 and how the pandemic not only provides lessons about the judicious use of antibiotics, but it also highlights another global health threat that has been playing out in slow motion: the mounting threat of antimicrobial resistance that annually claims 700,000 lives as the world’s arsenal of antibiotics and antifungal medication lose their ability to vanquish dangerous pathogens. There will be discussions focused on studies, and what may be the epidemiological impact of COVID/CDI in post hospital care and much more.
Our two guests, Teena Chopra, MD, MPH and Glenn Tillitson, PhD,FIDSA, will be discussing how C. diff. infections correlate with COVID-19 and how the pandemic not only provides lessons about the judicious use of antibiotics, but it also highlights another global health threat that has been playing out in slow motion: the mounting threat of antimicrobial resistance that annually claims 700,000 lives as the world’s arsenal of antibiotics and antifungal medication lose their ability to vanquish dangerous pathogens. There will be discussions focused on studies, and what may be the epidemiological impact of COVID/CDI in post hospital care and much more.
Join us in Part II of this educational discussion with guests Maureen Spencer, M.Ed, BSN, RN, CIC, FAPIC and Denise Graham discussing a safe, continuous, green, and real-time technology. Learn how a room’s ambient humidity and oxygen naturally present in the environment can significantly reduce the levels of environmental bio-burden in the air and on surfaces while working in occupied spaces.The use of the Synexis technology is similar to providing an immune system for a building. Evidence-based microbial reductions and research will be shared.
Join us with guests Maureen Spencer, M.Ed, BSN, RN, CIC, FAPIC and Denise Graham in discussing a safe, continuous, green, and real-time technology. Learn how a room’s ambient humidity and oxygen naturally present in the environment can significantly reduce the levels of environmental bio-burden in the air and on surfaces while working in occupied spaces.The use of the Synexis technology is similar to providing an immune system for a building. Evidence-based microbial reductions will be shared.
Join us with our Host, Nancy Caralla and our special Guest Host, Kevin Hersh, International Health Coach who will discuss ways to move forward past a long-term illness, and a long-term negative mind-set. Taking a moment to reflect, step back, evaluate, and look for the assets and positives in moving forward. Learn how to let the past go and embrace the new opportunities each day delivers. It takes strength, will, and the determination to step into the light and out of the darkness of the illness that paralyzes a healthy individual. Join us and take a step in a new direction.
Join us with our guests; With Doctor Teena Chopra, MD,MPH,FACP,FIDSA,FSHEA Associate Professor of Medicine,Division of Infectious Diseases, Corporate Medical Director, Infection Prevention,Epidemiology,and Antibiotic Stewardship ,DMC and WSU Director,Infection Prevention,Epidemiology and Antibiotic Stewardship,Vibra Hospital
Dr. Chopra will lead the discussion with an overview of a C. difficile infection followed by Alba Muhlfeld, and Renata Johnson, C. diff. Survivors both sharing their journey and providing key-points to our global listeners.
Join us with our two guests: Dr Yannick Pletan, Independent Director Clinical development specialist,Doctor of medicine, and Georges Gaudriault, Scientific Director, PhD in molecular pharmacology. Both Dr. Pletan and Gaudriault will introduce and discuss DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, announced the inclusion of the first patient in the Phase II trial testing DNV3837. DNV3837 targets the treatment of Clostridioides difficile (C. diff. ) infections (CDI), a disease classified as a priority by the WHO and one of the global leading causes of healthcare-related infections*. DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site.
Join us with our two guests: Dr Yannick Pletan, Independent Director Clinical development specialist,Doctor of medicine, and Georges Gaudriault, Scientific Director, PhD in molecular pharmacology. Both Dr. Pletan and Gaudriault will introduce and discuss DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, announced the inclusion of the first patient in the Phase II trial testing DNV3837. DNV3837 targets the treatment of Clostridioides difficile (C. diff. ) infections (CDI), a disease classified as a priority by the WHO and one of the global leading causes of healthcare-related infections*. DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site.
PART II The 2019–20 coronavirus pandemic is a pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, Hubei, China in December 2019. Join Our Guest: Maureen Spencer, RN, M.Ed, CIC, will be joining us to continue discussing the coronavirus (COVID-19) through Prevention, Symptoms, and the global healthcare focus.
The 2019–20 coronavirus pandemic is a pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, Hubei, China in December 2019. Join Our Guest: Maureen Spencer, RN, M.Ed, CIC, who will be discussing the coronavirus (COVID-19) an introduction through Prevention, Symptoms, and the global healthcare focus.
Join us with guests: Leigh Veasey, Sales Director - North America and Wendy Brady, Marketing Director - North America of Intellego Technologies. Both guests will be discussing UVC disinfecting, the use of UVC the use of dosimeter indicators in the healthcare environment. Learn more about dosimeter indicators, verification to ensure that UVC disinfection and devices are reaching their intended targets. Infection Prevention data shared that you will not want to miss!
Join us with guests: Leigh Veasey, Sales Director - North America and Wendy Brady, Marketing Director - North America of Intellego Technologies. Both guests will be discussing UVC disinfecting, the use of UVC the use of dosimeter indicators in the healthcare environment. Learn more about dosimeter indicators, verification to ensure that UVC disinfection and devices are reaching their intended targets. Infection Prevention data shared that you will not want to miss!
The 2019–20 coronavirus pandemic is a pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, Hubei, China in December 2019. Join us with our guests, Dr. Teena Chopra, MD, MPH and Jennifer Wood, a C. diff. Survivor as we introduce the COVID-19, compare and contrast the precautions, treatments, and environmental safety for both infectious diseases.
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
Join us with our guest: Mrs. Courtney Jones, Upstream Marketing Manager and Senior Project Manager at Rebiotix, a Ferring Pharmaceuticals company, focused on harnessing the power of the human microbiome to treat debilitating diseases. Mrs. Jones will be discussing and explaining the Microbiome. What Microbes are and the difference between the good, bad, and in between and what the Microbiome has to do with C.diff. treatment. There is a lot to learn about the science of the Microbiome and Mrs. Jones will certainly be educating us on this episode.
Join us with our guest: Mrs. Courtney Jones, Upstream Marketing Manager and Senior Project Manager at Rebiotix, a Ferring Pharmaceuticals company, focused on harnessing the power of the human microbiome to treat debilitating diseases. Mrs. Jones will be discussing and explaining the Microbiome. What Microbes are and the difference between the good, bad, and in between and what the Microbiome has to do with C.diff. treatment. There is a lot to learn about the science of the Microbiome and Mrs. Jones will certainly be educating us on this episode.
Join your host, Nancy C. Caralla with Members of the C Diff Foundation as they discuss the education and advocacy, and support programs available to patients, families, and clinicians worldwide.
Join us with our Host, Nancy Caralla and our special Guest Host, Kevin Hersh, International Health Coach who will discuss ways to move forward past a long-term illness, and a long-term negative mind-set. Taking a moment to reflect, step back, evaluate, and look for the assets and positives in moving forward. Learn how to let the past go and embrace the new opportunities each day delivers. It takes strength, will, and the determination to step into the light and out of the darkness of the illness that paralyzes a healthy individual. Join us and take a step in a new direction.
Learning ways to reduce stress and manage time is helpful to the caregiver. People who neglect their own needs and forget to nurture themselves are at danger of falling into fatigue and high stress. There are important basic self care strategies that can keep you functioning well and ready for life's challenges. There are times when people spend their time only taking care of others can be at risk for getting burned out on all the giving, which makes it more difficult to care for others or themselves. Taking time to care for yourself regularly can make you a better caretaker for others. Join us with guests Linda Jablonski, MS,BSN,BC-RN, and Barbara Baker Schaefer, MSW, as we discuss several different ways to focus on self-care, the balance of leisure time in your schedule - making time for yourself, family, and friends.
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
Join us with our guest: Jennifer W., a fellow-C. diff. Survivor, as we discuss positive changes, both big and small, that may help improve the way that you feel during any wellness-draining illness.
Join Your Host, Nancy Caralla, with Guest Host Kevin Hersh as they discuss proven ways to prevent the FLU virus and more.
Join us with our special guest, Sabine Hazan, MD, a gastroenterology specialist in Ventura, CA and has been practicing for 22 years. Dr. Hazan will be explaining Clinical Trials and how individuals can participate in trials to help themselves -- to help others. There will also be discussions about C. difficile infections, recurrent CDI's, and the Microbiome and why it is so important in our health today. We look forward to receiving your questions at info@cdifffoundation.org and enjoy the episode.
Join us with our guest: Jennifer W., a fellow-C. diff. Survivor, as we discuss positive changes, both big and small, that may help improve the way that you feel during any wellness-draining illness.
Join Your Host, Nancy Caralla, with Guest Host Kevin Hersh as they discuss proven ways to prevent the FLU virus and more.
This special episode with Host Nancy Caralla and Guest Host Kevin Hersh turn up the volume with C. diff. Survivors Jennifer W. and Robin S. as they share their journey through a C. diff. infection.
Join us with our guests: Caitlin Stowe is a master’s prepared infection preventionist currently employed with PDI as the Clinical Affairs Research Manager and Megha Patel is a Senior Product Manager with PDI, focused on new product development. Both professionals will be discussing innovation in C. difficile prevention.
Join us with guest, L. Clifford McDonald, MD. Dr. McDonald, MD graduated from Northwestern University Medical School. He completed a medical microbiology fellowship at Duke University and is a former member of CDC’s Epidemic Intelligence Service. Dr. McDonald is currently the Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC. He has first-authored or co-authored over 100 peer-reviewed publications on subjects related to healthcare and infectious disease epidemiology.
Listen in as Dr. McDonald discusses the Centers for Disease Control and Prevention (CDC) newly released report; 2019 Antibiotic Resistance Threats in the United States and what that means in the C. difficile community.
Join us with our guest: Maureen Spencer, RN, M.Ed., CIC joining us to discuss an array of important topics: 1. Overuse and inappropriate prescribing of antibiotics worldwide is leading to the global healthcare issue of antibiotic resistance. 2. Empiric antibiotics are used consistently in healthcare when infection is suspected 3. Empiric antibiotics are prescribed to cover gram positive, gram negative and yeast infections until the final lab result is available 4. Overuse of antibiotics adversely effect the normal flora and microbiome in the body depleting colonies of bacteria that are necessary for digestion and protection. 5. When the microbiome is depleted other resistant species overgrow on the skin and in the systems of the body, especially the gut. 6. Multiple Drug Resistant organisms MDRO include MRSA, VRE, ESBL and CRE that will grow in patients who have been on antibiotics AND MUCH MORE.
This special episode with Host Nancy Caralla and Guest Host Kevin Hersh turn up the volume with C. diff. Survivors Jennifer W. and Robin S. as they share their journey through a C. diff. infection.
Join Us with guest: Karl Kappeler, MS, RPh, FASHP Director, Medical Affairs of Azurity Pharmaceuticals. and will be discussing C. difficile infections, C. diff. treatment options and the Azurity Pharmaceuticals organization with its FDA approved product.
Listen in as we learn more about the Company’s history, their unique product offerings that help pharmacists compound drugs, and product information for FIRVANQ, their FDA approved vancomycin oral solution.
Join Our Guests: Kerrie Davies, Principal Clinical Scientist, and Visiting Research Fellow, Leeds Teaching Hospitals NHS Trust and the University of Leeds, and Dr. Jane Freeman, Clinical Scientist and Visiting Research Fellow, Leeds Teaching Hospitals NHS Trust and the University of Leeds. HEE/NIHR ICA Clinical Lecturer as they discuss Antimicrobial Resistance.--the who, what, how, and why of AMR and the importance of this topic. You won't want to miss this episode -Antibiotic Resistance is everyone's business!
Join us with guest, L. Clifford McDonald, MD. Dr. McDonald, MD graduated from Northwestern University Medical School. He completed a medical microbiology fellowship at Duke University and is a former member of CDC’s Epidemic Intelligence Service. Dr. McDonald is currently the Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC. He has first-authored or co-authored over 100 peer-reviewed publications on subjects related to healthcare and infectious disease epidemiology.
Listen in as Dr. McDonald discusses the Centers for Disease Control and Prevention (CDC) newly released report; 2019 Antibiotic Resistance Threats in the United States and what that means in the C. difficile community.
Join us and learn from our guests; Dr. Clifford McDonald, MD, Senior Advisor for Science and Integrity, Division of Healthcare Quality Promotion at the CDC with main interests in epidemiology and prevention of Healthcare-Associated Infections, especially Clostridium difficile infections, and the prevention of antimicrobial resistance. And Dr. Arjun Srinivasan, MD, Associate Director for Healthcare-Associated Infection prevention programs in the Division of Healthcare Quality Promotion at CDC's National Center for Emerging and Zoonotic Infectious Disease. Listen in as these two stellar Physicians discuss the topics of Clostridium difficile infections and Antibiotic usage, two important issues with potential solutions facing the citizens on a global level..
Join us with our guests: Caitlin Stowe is a master’s prepared infection preventionist currently employed with PDI as the Clinical Affairs Research Manager and Megha Patel is a Senior Product Manager with PDI, focused on new product development. Both professionals will be discussing innovation in C. difficile prevention.
Join us with our guests: Caitlin Stowe is a master’s prepared infection preventionist currently employed with PDI as the Clinical Affairs Research Manager and Megha Patel is a Senior Product Manager with PDI, focused on new product development. Both professionals will be discussing innovation in C. difficile prevention.
Join us with Guest: Henry R Herrera Jr., MD, a Gastroenterology specialist. Dr. Herrera will be discussing the complications of a C. diff. infection and Inflammatory Bowel Disease (IBD). His professional experience and expertise is in Gastroenterology and places Dr. Herrera at the forefront of diagnosing, treating, and caring for patients experiencing the symptoms of the many diagnosis associated with the Gastrointestinal system.
Join us with our guest: Maureen Spencer, RN, M.Ed., CIC joining us to discuss an array of important topics: 1. Overuse and inappropriate prescribing of antibiotics worldwide is leading to the global healthcare issue of antibiotic resistance. 2. Empiric antibiotics are used consistently in healthcare when infection is suspected 3. Empiric antibiotics are prescribed to cover gram positive, gram negative and yeast infections until the final lab result is available 4. Overuse of antibiotics adversely effect the normal flora and microbiome in the body depleting colonies of bacteria that are necessary for digestion and protection. 5. When the microbiome is depleted other resistant species overgrow on the skin and in the systems of the body, especially the gut. 6. Multiple Drug Resistant organisms MDRO include MRSA, VRE, ESBL and CRE that will grow in patients who have been on antibiotics AND MUCH MORE.
Join us with guest Sahil Khanna, MD, M.B.B.S Dr. Khanna, MD, MBBS, is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN. Dr. Khanna will be discussing Antibiotics treating C. difficile infections, clinical trials, and Investigations Treatments.
Join us with guests Ron Romano, RN and Jenn Robke, RN as they discuss the main question in today's episode is not what products are being utilized to address germs and bacteria. Listen in to learn more
Join our guests Beatrix M. Babcock, MS HSA, LPN and Michael Kupneski is the R and ;D Section Head for Procter and Gamble Professional. Both guests will be discussing the importance of disinfection and sanitizing soft surfaces in health care environments.
Guest Kevin Hersh, an International Health Coach, joins us to discuss the tools that are able to create positive effects while coping with the stressors of returning back to school, and maintaining the balance in life.
Professor Simon Cutting joins us and shares his thoughts and scientific research focused on C.difficile prevention, treatments, and probiotics. The C.diff. infection concept of 20 years ago is not what it is today. Professor Cutting reviews the landscape of C.difficile from the farms, animals, to humans and the differences from country to country.
Join us with guest Bernat Olle, MS, PhD as we discuss Defined Bacterial Consortia for Prevention of a C. difficile infection (CDI) Recurrence.
Professor Simon Cutting joins us and shares his thoughts and scientific research focused on C.difficile prevention, treatments, and probiotics. The C.diff. infection concept of 20 years ago is not what it is today. Professor Cutting reviews the landscape of C.difficile from the farms, animals, to humans and the differences from country to country.
Join us with our guest: Ms. Courtney Jones, Upstream Marketing Manager and Senior Project Manager at Rebiotix, a Ferring Pharmaceuticals company, focused on harnessing the power of the human microbiome to treat debilitating diseases. Ms. Jones will be discussing and explaining the Microbiome. What Microbes are and the difference between the good, bad, and in between and what the Microbiome has to do with C.diff. treatment. There is a lot to learn about the science of the Microbiome and Ms. Jones will certainly be educating us on this episode, Researching Bugs as Drugs to Fight C.diff..
Join us with our guest: Ms. Courtney Jones, Upstream Marketing Manager and Senior Project Manager at Rebiotix, a Ferring Pharmaceuticals company, focused on harnessing the power of the human microbiome to treat debilitating diseases. Ms. Jones will be discussing and explaining the Microbiome. What Microbes are and the difference between the good, bad, and in between and what the Microbiome has to do with C.diff. treatment. There is a lot to learn about the science of the Microbiome and Ms. Jones will certainly be educating us on this episode, Researching Bugs as Drugs to Fight C.diff..
The Centers for Medicare and Medicaid Services (CMS) regulations, revised in the past few years, will improve infection control in long term care facilities and must be fully implemented by November 2019. Improved infection control practices in Long Term Care Facilities (LTCF’s) should result in a reduction in healthcare-associated infections, including C. difficile infections.
In 2019, LTCFs participating in Medicare must be in full compliance with part 483.80 of title 42 of the Code of Federal Regulations (CFR). The IPCP at a single LTCF was evaluated for compliance with these revised regulations.
Join our guests Doe Kley, RN, CIC, MPH and R. Deane Kirchner, RN as they discuss and review The infection control revisions in the CMS requirements for LTCF’s. * The unique challenges that LTCF’s face with infection control and antimicrobial stewardship.* Evidence-based recommendations for the prevention of C. diff in LTCF’s. and much more.
The Centers for Medicare and Medicaid Services (CMS) regulations, revised in the past few years, will improve infection control in long term care facilities and must be fully implemented by November 2019. Improved infection control practices in Long Term Care Facilities (LTCF’s) should result in a reduction in healthcare-associated infections, including C. difficile infections.
In 2019, LTCFs participating in Medicare must be in full compliance with part 483.80 of title 42 of the Code of Federal Regulations (CFR). The IPCP at a single LTCF was evaluated for compliance with these revised regulations.
Join our guests Doe Kley, RN, CIC, MPH and R. Deane Kirchner, RN as they discuss and review The infection control revisions in the CMS requirements for LTCF’s. * The unique challenges that LTCF’s face with infection control and antimicrobial stewardship.* Evidence-based recommendations for the prevention of C. diff in LTCF’s. and much more.
Join us with guest Sarah Mische, PhD as we discuss the value and importance of Clinical Trials worldwide. Learn about the different phases, the efficacy, patient safety, and research and development that begins the process. Clinical Trials have a beginning, evaluations, FDA meetings, with time well spent by dedicated Science professionals, Clinicians, Health care Providers, and the individuals who are accepted to participate in the studies. It will be an episode you won't want to miss! Listen in and learn how we can help them - to help you - to help others.
Join us with guest Sarah Mische, PhD as we discuss the value and importance of Clinical Trials worldwide. Learn about the different phases, the efficacy, patient safety, and research and development that begins the process. Clinical Trials have a beginning, evaluations, FDA meetings, with time well spent by dedicated Science professionals, Clinicians, Health care Providers, and the individuals who are accepted to participate in the studies. It will be an episode you won't want to miss! Listen in and learn how we can help them - to help you - to help others.
Join us with guest Dr. David Lyerly, PhD - Co-Founder, CSO of TechLab. Dr. Lyerly will be discussing C.diff. (C.difficile) in the IBD Patient ~ the research,clinical assays for enteric and autoimmune diseases.
Dr. Lyerly will also be discussing the symptoms and lab testing focused on a C. difficile infection in the IBD patient.
If you have specific questions to be shared with our guests during the show - please e-mail them ahead of time to info@cdifffoundation.org Thank you.
Join us with guests Dr. David Lyerly, PhD , PhD - Co-Founder, CSO of TechLab and James H. Boone, M.S.,Director of Collaborative Studies, Senior Research Scientist at TechLab. Both guests will be discussing C.diff. (C.difficile) research,clinical assays for enteric and autoimmune diseases including inflammatory bowel diseases, CDI Guidelines. Dr. Lyerly, PhD and James H. Boone will also be discussing the symptoms and lab testing focused on a C. difficile infection. If you have specific questions to be shared with our guests during the show - please e-mail them ahead of time to info@cdifffoundation.org Thank you.
Join your host Nancy C. Caralla with guest host Kevin Hersh as we discuss Positive Healthy Habits that helped you and your family during and after a C.diff. infection and all other wellness draining illnesses. The episode will be accepting call in opportunities from YOU, our listening audience. 1-866-472-5792 It is time to let your voices be heard and share your inspiration with others around the globe fighting their way through illnesses that have changed lives forever. Thank you for participating!
Join us with our guests Elizabeth A.Myers,BSN, RN and Wendy Benson, MBA, OTR/L as we discuss the challenges of today's healthcare and their newly published book, The Confident Patient which answers the many questions and guides patients and families through the healthcare mazes. Have your tablets, pen and paper ready to jot down notes as we discuss healthcare solutions and helpful information for the entire family.
Join us as our guests Kerrie Davies, Principal Clinical Scientist and Visiting Research Fellow, Leeds Teaching Hospitals NHS Trust and University of Leeds and Professor Mark H. Wilcox, MD, Professor of Medical Microbiology, University of Leeds, Consultant / Head of Microbiology Research & Development, Leeds Teaching Hospitals NHS Trust discuss accurate diagnosis of a C.difficile infection. Both guests are dedicated professionals in the C.difficile community and have played an instrumental part of raising C.diff.. awareness through their research, and development worldwide.
Join us with our guests Sue Barnes, RN, BSN, CIC, FAPIC, Wesley LaPorte -- as they discuss the risks of contamination of cell phones and tablets. Tune in to learn more about the type of germs that can be transferred from mobile devices to individuals. Best ways to disinfect mobile devices to decrease risks.
Power of Positive, a mindset that will take anyone from today forward. Listen to C.diff. Survivors as they share their journey. Learn how they found coping skills to help them and their families move from the paralyzing experience to stepping back into life -- the recovery phase. This will be a open CALL IN episode. Join your Host Nancy C. Caralla with Co-Host Kevin Hersh as we discuss the paths that make sense when life just doesn't.
Reducing Surgical Site Infection Risk: Intraoperative Surgical Infection Prevention and Wound Edge Contamination with guests Sue Barnes, RN, BSN, CIC, FAPIC and Jonathan Coe, President and CEO of Prescient Surgical. Sue and Jon will be joining us to discuss surgical site infection prevention, the risks and how infections impact the patient and families. Join us and expand your knowledge on skilled and new options available to prevent adverse effects from surgical procedures.
Join us with guest Ron Romano, RN. Ron's background in healthcare and passion for Infection Prevention and Epidemiology is an asset to many. The main question in today's episode is not what products are being utilized to address germs and bacteria. The question is -- how do you, a caregiver, become part of the solution in disinfection? How does a Hospital Administrator become part of the solution in disinfection? And those responsible in environmental departments in long-term-care, clinics, and out-patient centers -- how are they part of the disinfection solution? Listen in to learn more about this important topic and how each of us play a major role in universal disinfection to be part of the solution to this global problem. Ron is the Owner, President,CEO of Safety Net LLC a national healthcare safety consulting and distribution company providing unique product solutions to mitigate risk associated to infections and secure safer living and work environments.
Power of Positive, a mindset that will take anyone from today forward. Listen to C.diff. Survivors as they share their journey. Learn how they found coping skills to help them and their families move from the paralyzing experience to stepping back into life -- the recovery phase. This will be a open CALL IN episode. Join your Host Nancy C. Caralla with Co-Host Kevin Hersh as we discuss the paths that make sense when life just doesn't.
Join us as our guests Dr. Mark Stine, DO, FACOI, and Celeste Wiggins, MBA, will discuss the state- of- the- art Footwear Sanitizing Station and New Technology Eliminating Pathogens. Patho3gen Solutions focus is on prevention, not treatment. They are passionate about saving lives and, through hard work, determination, and world-class state-of-the-art technology, their dream has become a reality. Many technologies aid in reducing the infections that cause large numbers of remittances and even death of patients. Unfortunately, the current protocol in healthcare is reactive and for many, that’s too late. Approximately 300 people die every day, over 100,000 annually. Today’s infection control programs such as hand hygiene, cleaning and disinfection – are not eliminating the number of HAIs coming into hospitals. Learn about the science behind the product, the studies, and research from our guests and topic experts, Dr. Mark Stine and Celeste Wiggins.
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
Join us with co Author, Jay Papasan of The 1 Thing. Our guest will be discussing ways to move forward, personal growth, habits and reaching goals in life. If you have a questions for our guest, please e-mail it to info@cdifffoundation.org and be listening for your answer during our live broadcast!
Join us with guests Dr. David Lylerly, PhD - Co-Founder, CSO of TechLab and James H. Boone, M.S.,Director of Collaborative Studies, Senior Research Scientist at TechLab. Both guests will be discussing C.diff. (C.difficile) research,clinical assays for enteric and autoimmune diseases including inflammatory bowel diseases, CDI Guidelines. Dr. Lylerly and James H. Boone will also be discussing the symptoms and lab testing focused on a C. difficile infection. If you have specific questions to be shared with our guests during the show - please e-mail them ahead of time to info@cdifffoundation.org Thank you.
Guest Host: Kevin Hersh and guests Susan Maboe Johnston, RN BS and Diana Gallagher, MS, RN, CWOCN CFCN will be discussing the risks that lead to infection in the hospital, and other healthcare settings, including the challenges of skin decontamination in the hospital or acute care setting.
Join our Guest Host, Kevin Hersh with guests Dr. Nam Tran (UC Davis), and Dr. Chris Newhouse (Roche) as they discuss the Role of Diagnostics In Supporting Antibiotic Stewardship Goals. Dr. Newhouse will be introducing Antibiotic Resistance with Dr. Tran who will be discussing Antibiotic Stewardship in Action followed with a group discussion on the role of Diagnostics in Antibiotic Stewardship.
Join us with our guests, Katie Stewart, Director of Health Care Ratings and Lauren Bailey, Communications Manager Manager at The Leapfrog Group. Katie and Lauren will be discussing the available resources that patients, families and caregivers can access for free to make informed decisions about their care. The discussion will also introduce the Leapfrog Group and the powerful insight it offers. At least 200,000 people die from preventable medical errors every year. Founded in 2000 by large employers and other purchasers, The Leapfrog Group is a national nonprofit organization driving a movement for giant leaps forward in the quality and safety of American health care. Working with the nation’s best patient safety experts, The Leapfrog Group provides an opportunity for hospitals to measure the results of their efforts to improve patient care.
Join us with our guest Dr. Cliff Yahnke, Ph.D. as we discuss the problem - Current environmental disinfection methods are applied at discrete moments in time (ie.episodically). The results of achieving a clean room are short-lived as harmful bacteria re-populate the space. The Solution - Indigo-Clean offers a solution that continuously disinfects the environment and bolsters your current infection prevention efforts. And the Clinical / Laboratory Evidence and data on informational documents and research findings that either report directly on the effectiveness of the Indigo-Clean technology, or support the importance of a clean environment and the ultimate goal of reducing Healthcare Acquired Infections (HAIs). Bactericidal Performance Testing of Indigo-Clean Upon Bacterial Species, Reducing SSI Through Improved Environmental Hygiene, and A Revolutionary New Way to Battle HAIs, Shining A Light on Continuous Disinfection and more.
Join our Guest Host, Kevin Hersh with guests Dr. Nam Tran (UC Davis), and Dr. Chris Newhouse (Roche) as they discuss the Role of Diagnostics In Supporting Antibiotic Stewardship Goals. Dr. Newhouse will be introducing Antibiotic Resistance with Dr. Tran who will be discussing Antibiotic Stewardship in Action followed with a group discussion on the role of Diagnostics in Antibiotic Stewardship.
Join us with Guests: Sue Barnes, RN, BSN, CIC, FAPIC and Bill Spannhake, PhD as these two professionals discuss Nasal Decolonization and Reducing Patient Infection Risk. Overview Nasal Decolonization Sue and Dr. Spannhake will share and present Key Topics: The role of nasal decolonization in patient infection prevention and control, Best Practices in Hospital Nasal Decolonization. This episode is Sponsored by Global Life Technologies - Nozin®
Join us with guest host, Kevin Hersh, Int'l Health and Wellness Coach as we discuss the good vs not-so-good goals, Moving out of the comfort zone, and taking steps in the right direction to reach our goals.
Join us with guest Sarah Mische, PhD as we discuss the value and importance of Clinical Trials worldwide. Learn about the different phases, the efficacy, patient safety, and research and development that begins the process. Clinical Trials have a beginning, evaluations, FDA meetings, with time well spent by dedicated Science professionals, Clinicians, Health care Providers, and the individuals who are accepted to participate in the studies. It will be an episode you won't want to miss! Listen in and learn how we can help them - to help you - to help others.
Join us as Brandon and Nicole Bookstaver discuss Managing Clostridium difficile infection at the point of discharge - We will be discussing transitions of care, importance of adherence and we'll touch on strategies of prevention and prophylaxis for patients who have already had a case of CDI (aka secondary prevention).
Join us with guests Ken Blount, Ph.D., Chief Scientific Officer and Paul Plumb, Head of Clinical Operations from Rebiotix. Ken and Paul will discuss the gut microbiome and the role it plays in overall health and Rebiotix’s goal to rehabilitate the gut microbiome by utilizing their unique Microbiota Restoration Therapy™ (MRT) Platform through its extensive clinical trial program. The science behind their products, product development and how patients are an important part of helping develop new drugs will also be discussed.
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
Join us with guest Kevin Hersh, Int'l Life Coach as we discuss lifestyle methods to cope with Seasonal Affective Disorder. What is Seasonal Affective Disorder (SAD)? Seasonal Affective Disorder (SAD) is commonly referred to as the winter blues or winter depression. People typically experience it starting in the fall and all through winter. Sunny summer days and warm weather can improve your mood, so it makes sense that the time change combined with cooler weather and shorter days can have impact mental health. Seasonal Affective Disorder is recognized as a type of depression and can cause increased anxiety, sadness and stress, lack of enjoyment in regular activities, feelings of isolation, mood swings, and several other symptoms that can take over your life. There are ways to help deal with it, so gather your notebook and electronic devices to takes notes as we discuss ways to cope with Seasonal Affective Disorder(SAD).
Join us with our guest Carolyn Twomey, BSN, RN as we discuss infection prevention, and antibiotic stewardship in health care settings.
Join us with our guest, Neal I. Muni, MD, MSPH, President and CEO of CutisPharma as we discuss CutisPharma and their new FDA approved product FIRVANQ ™ Listen in as we learn more about the Company’s history, their unique product offerings that help pharmacists compound drugs, and product information for FIRVANQ ™, their recently approved vancomycin oral solution.
This episode is focused on using antibiotics wisely and how YOU can help in the fight of antibiotic resistance. Listen in as these two stellar Physicians discuss the topics of Clostridium difficile infections and Antibiotic usage. Important topics for citizens on a global level.
Join us with our guest Dr. Arjun Srinivasan, an Infectious Disease Doctor and the Associate Director of Healthcare Associated Infection Prevention Programs for the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention in Atlanta, Georgia -- as we introduce Healthcare Associated Infections and discuss the progress being made to prevent them and the goals in place to eliminate HAI's.
Join us as Dr. Balachandran discusses contaminated soft surfaces (e.g., carpeting, upholstery, material, etc..) and the hospital infection risks focused on soft surfaces found in this setting with methods and products to address transforming contaminated surfaces. Learn more about applied silver and the success in reducing microbial contamination during this in-depth conversation with Dr. Balachandran.
Join us with guest Sarah Mische, PhD as we discuss the value and importance of Clinical Trials worldwide. Learn about the different phases, the efficacy, patient safety, and research and development that begins the process. Clinical Trials have a beginning, evaluations, FDA meetings, with time well spent by dedicated Science professionals, Clinicians, Health care Providers, and the individuals who are accepted to participate in the studies. It will be an episode you won't want to miss! Listen in and learn how we can help them - to help you - to help others.
Learn about the importance of laboratory testing in the identification of a C. difficile Infection (CDI). with guests: Jeanine Thomas, President and Founder of the MRSA Survivors Network who is a survivor of both MRSA and C. diff. infections. Dr. Nathan A. Ledeboer, PhD, D(ABMM), Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health. Dr. Whitney R. Buckel, PharmD, BCPS who is the Infectious Diseases and Antimicrobial Stewardship Clinical Pharmacist at Intermountain Medical Center, and Dr. Steven Cagas, who will give us a brief overview of Roche Diagnostics as well as their new cobas® Cdiff Test.
Learn about the importance of laboratory testing in the identification of a C. difficile Infection (CDI). with guests: Jeanine Thomas, President and Founder of the MRSA Survivors Network who is a survivor of both MRSA and C. diff. infections. Dr. Nathan A. Ledeboer, PhD, D(ABMM), Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health. Dr. Whitney R. Buckel, PharmD, BCPS who is the Infectious Diseases and Antimicrobial Stewardship Clinical Pharmacist at Intermountain Medical Center, and Dr. Steven Cagas, who will give us a brief overview of Roche Diagnostics as well as their new cobas® Cdiff Test.
Our guests, Wesley LaPorte,and Sue Barnes, RN, BSN, CIC, FAPIC join us to discuss The Risk of Contaminated Cell Phones and Tablets In Healthcare. Healthcare professionals depend upon mobile electronic devices both inside and outside of the healthcare facilities. The mobile devices become the perfect surfaces to transport pathogens from one place, one room, and one patient to another. Wesley and Sue share up-to-date information on how handheld mobile devices can be cleaned and disinfected effectively.
Join us with guest David Kirschman MD FAANS, as we discuss Contaminated Operating Room Air and Surgical Infection Risk. Dr Kirschman will also discuss better air for healthcare - the mission of Aerobiotix, Inc. an innovative company driving leadership in advanced air quality products for the healthcare market. Aerobiotix, Inc. designs, develops, manufactures and markets novel technologies to build healthy environments worldwide.
Join us with guests Sam Trapani: President & Chief Executive Officer,Founder of Steriliz and Michelle L. Vignari RN, CIC Director of Infection Prevention and Disaster Preparedness for Thomson Health in Canandaigua, NY. Sam and Michelle will be discussing the Sterilize organization and Infection Prevention (rduvc.com) a leading supplier of ultraviolet-C light disinfection technology with the specific goal of developing area and surface disinfection methods and processes that are science based, quantitative and traceable. In addition, Steriliz has collected a significant amount of clinical data and has developed unique data analysis techniques, which provide closed loop feedback and management information for infection control practitioners. The company is based in Rochester, N.Y.
Join us with our guests Bruce Rippe, CEO of Trinity Guardion and Edmond A. Hooker, MD, DrPH as we discuss Healthcare Acquired Infections and how they lead to more than 720,000 illnesses and 75,000 deaths a year. In fact, more people die from HAIs each year than from automobile accidents. Furthermore, HAI's are a huge financial burden, adding $30 billion to annual healthcare costs. The American-made Trinity Patient Protection System gives hospitals the solution they need to reduce and eliminate HAI's. Launderable, reusable, cost-effective and eco-friendly, the Trinity System’s fluid-proof covers fit around beds, pillows, stretchers and physical therapy tables. Unlike typical disinfectant agents designed for hard surfaces, the Trinity System keeps bacteria off the porous surface of the mattress, as well as, the bed deck. When laundered to CDC standards, the Trinity System removes 99.99% of bacteria and has been proven to reduce C. diff infection rates by about 50%.
Join us with guest Sarah Mische, PhD as we discuss the value and importance of Clinical Trials worldwide. Learn about the different phases, the efficacy, patient safety, and research and development that begins the process. Clinical Trials have a beginning, evaluations, FDA meetings, with time well spent by dedicated Science professionals, Clinicians, Health care Providers, and the individuals who are accepted to participate in the studies. It will be an episode you won't want to miss! Listen in and learn how we can help them - to help you - to help others.
Join us with our guest Carolyn Twomey, BSN, RN as we discuss infection prevention, and antibiotic stewardship in health care settings.
Join us with our guest Carolyn Twomey, BSN, RN as we discuss infection prevention, and antibiotic stewardship in health care settings.
Join us with our guest, Maureen Spencer, RN, M.Ed., board certified in infection control (CIC) for over 30 years and currently the Director, Clinical Implementation at Accelerate Diagnostics, providing educational and consultative services to the sales and marketing teams in the U.S.. Maureen will be discussing why C.difficile infections is a significant infection in healthcare, the role of the Infection Preventionist and the importance of infection surveillance and testing in healthcare. Listen in as Maureen shares the key-points in preventing the spread of infections -- especially a C. difficile infection.
Join us with our guest, Maureen Spencer, RN, M.Ed., board certified in infection control (CIC) for over 30 years and currently the Director, Clinical Implementation at Accelerate Diagnostics, providing educational and consultative services to the sales and marketing teams in the U.S.. Maureen will be discussing why C.difficile infections is a significant infection in healthcare, the role of the Infection Preventionist and the importance of infection surveillance and testing in healthcare. Listen in as Maureen shares the key-points in preventing the spread of infections -- especially a C. difficile infection.
Join us with guest Kevin Hersh, Int'l Life Coach as we discuss lifestyle methods to cope with Seasonal Affective Disorder. What is Seasonal Affective Disorder (SAD)? Seasonal Affective Disorder (SAD) is commonly referred to as the winter blues or winter depression. People typically experience it starting in the fall and all through winter. Sunny summer days and warm weather can improve your mood, so it makes sense that the time change combined with cooler weather and shorter days can have impact mental health. Seasonal Affective Disorder is recognized as a type of depression and can cause increased anxiety, sadness and stress, lack of enjoyment in regular activities, feelings of isolation, mood swings, and several other symptoms that can take over your life. There are ways to help deal with it, so gather your notebook and electronic devices to takes notes as we discuss ways to cope with Seasonal Affective Disorder(SAD).
Join us as Dr. Dale Gerding, MD, an Infectious Disease specialist, researcher, professor, hospital epidemiologist, and one of the leading international experts on Clostridium diffiicle (C.diff.), will discuss his patented non-toxigenic Clostridium difficile (NTCD-M3) technology for the prevention and treatment of a C. diff. infection. Dr.Gerding currently owns patents and all rights to the development, manufacturing, regulatory, and clinical trial data for NTCD-M3. The lead pharmaceutical product, NTCD-M3, incorporating this technology has already completed Phase 1 & 2 Clinical Trials, has FDA Fast Track approval, is expected to be eligible for Breakthrough Therapy Designation by the FDA for a Phase 3 Clinical Trial, and to be eligible for Reference Product Exclusivity for 12 years for an approved biologics license application.
Join us with our guest, Stuart Johnson, MD as we discuss, 'What is C.difficile?', how a C.diff. infection CDI can be prevented, Vancomycin - the preferred treatment available today and being utilized to treat this infection and much more.
Join us with our two guests: Brad Lucus and Hanson Meyer of Hygeia as they discuss a novel approach to killing C. difficile (C;diff.) using electrochemistry instead of conventional chemistry in cleaning and sanitizing. The benefits of electrochemistry to cleaning and the limitations of electrochemistry will be discussed. We will also talk about the safety advantages of using electrochemistry and where it is currently being used today to combat germs. We will discuss recent studies from Europe and America regarding the limitations of conventional chemistry in cleaning and the growing use of electrochemistry.
Our guests Nancy Foster, Vice President, Quality and Patient Safety Policy, American Hospital Association and Edmond A. Hooker, MD, DrPH will be discussing the Centers for Medicare and Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services, CMS 2019 Inpatient Prospective Payment System (IPPS) proposed rule – which includes proposals to de-duplicate measures across the five hospital quality reporting programs.
This special live broadcast discussion will be about the CMS’ recent proposals for Healthcare-associated infection (HAI) measures and to provide facts that will bring forth a better understanding of the proposed rule.
Caterina Oneto, MD and Paul Feuerstadt, MD will be discussing C. difficile infections and the latest data shared focused on CDI's that was presented during Digestive Disease Week 2018 along with Clinical Trials in progress that address C.diff. infection prevention, treatments and recurrent C.diff. infection treatments.
Join your host, Nancy C. Caralla with Members of the C Diff Foundation as they discuss the education and advocacy, and support programs available to patients, families, and clinicians worldwide.
Join us with guest Kevin Hersh, Int'l Life Coach as we discuss life altering events and how to remove the anchor and replace it with a launch pad to continue moving forward.
Join our guest, Josh Haas, ACE Certified Personal Trainer, Health and Wellness Specialist, as we discuss 'C.diff. Hunger and Way to Prevent It.' Nutrition, dietary challenges occur during any G.I. illness and long-term diagnosis. Josh will be discussing the importance of maintaining good nutrition during any illness, the ways to combat the hunger and prevent additional healthcare deficiencies from occurring. It is an outstanding episode so grab your paper and pen, your tablet, and notebook to take important notes that will help guide you and your loved ones through illnesses that disrupt normal dietary intake.
Join us with our three guests - Stools Game Creator, Gareth @StoolsGame along with Melvin Bell of @FocusGames and Dr Jonathan Sutton, Consultant Gastroenterologist at @BCUHB! Tune in at 1:00 p.m. ET and 6:00 p.m. (GMT) UK time, on Tuesday , May 29th, 2018.
Join us with our Guest, Synthetic Biologics’ Joseph Sliman, MD, MPH, Chief Medical Officer, as we discuss the Company’s novel microbiome-focused product candidates. Protection and preservation of the natural gut microbiome continues to be a key role in the prevention of certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel disease (IBS). Synthetic Biologics is developing two lead microbiome-focused drugs poised for Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used IV beta-lactam antibiotics for the prevention of CDI, overgrowth of pathogenic organisms and the emergence of antimicrobial resistance AMR, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel disease with constipation (IBS-C).
Join us with our guest Carolyn Twomey, BSN, RN as we discuss infection prevention, and antibiotic stewardship in health care settings.
Join Us with Guest Kevin Hersh, Int'l Health Coach helping individuals around the world reach their life-long goals during sickness and in health. If you have any questions for Kevin send them before the program for Kevin's answers to help you. info@cdifffoundation.org
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
Join us with our guest Alex Huang, founder of Quellthera, will discuss the new science that is revealing how incredibly smart and adaptable bacteria are. Our human microbiome and immune system have immensely complex interactions that have evolved over millions of years. The rapid immune response of living plant cells has shown us a strategy for stopping the attack of harmful bacteria without causing collateral damage to beneficial microflora. This reaction is also part of the human evolutionary diet and, unlike antibiotics, simultaneously moderates toxin assaults, intestinal vulnerability and inflammatory responses. Modern methods are finally enabling us to understand processes such as quorum sensing and other molecular interactions that pave the way to new medicines that can effectively address infections like C. diff. without promoting superbugs
Join us with our guests Bruce Rippe, CEO of Trinity Guardion and Edmond A. Hooker, MD, DrPH as we discuss Healthcare Acquired Infections and how they lead to more than 720,000 illnesses and 75,000 deaths a year. In fact, more people die from HAIs each year than from automobile accidents. Furthermore, HAI's are a huge financial burden, adding $30 billion to annual healthcare costs. The American-made Trinity Patient Protection System gives hospitals the solution they need to reduce and eliminate HAI's. Launderable, reusable, cost-effective and eco-friendly, the Trinity System’s fluid-proof covers fit around beds, pillows, stretchers and physical therapy tables. Unlike typical disinfectant agents designed for hard surfaces, the Trinity System keeps bacteria off the porous surface of the mattress, as well as, the bed deck. When laundered to CDC standards, the Trinity System removes 99.99% of bacteria and has been proven to reduce C. diff infection rates by about 50%.
Join us with our guest Carolyn Twomey, BSN, RN as we discuss infection prevention, and antibiotic stewardship in health care settings.
Join your host, Nancy C. Caralla with Members of the C Diff Foundation as they discuss the education and advocacy, and support programs available to patients, families, and clinicians worldwide.
Join your host, Nancy C. Caralla with Members of the C Diff Foundation as they discuss the education and advocacy, and support programs available to patients, families, and clinicians worldwide.
Join us with guests Ken Blount, Ph.D., Chief Scientific Officer and Paul Plumb, Head of Clinical Operations from Rebiotix. Ken and Paul will discuss the gut microbiome and the role it plays in overall health and Rebiotix’s goal to rehabilitate the gut microbiome by utilizing their unique Microbiota Restoration Therapy™ (MRT) Platform through its extensive clinical trial program. The science behind their products, product development and how patients are an important part of helping develop new drugs will also be discussed.
Join us with our guest, Neal I. Muni, MD, MSPH, President and CEO of CutisPharma as we discuss CutisPharma and their new FDA approved product FIRVANQ ™ Listen in as we learn more about the Company’s history, their unique product offerings that help pharmacists compound drugs, and product information for FIRVANQ ™, their recently approved vancomycin oral solution.
Join us with our guest, Neal I. Muni, MD, MSPH, President and CEO of CutisPharma as we discuss CutisPharma and their new FDA approved product FIRVANQ ™ Listen in as we learn more about the Company’s history, their unique product offerings that help pharmacists compound drugs, and product information for FIRVANQ ™, their recently approved vancomycin oral solution.
Join your host, Nancy C. Caralla with Members of the C Diff Foundation as they discuss the education and advocacy, and support programs available to patients, families, and clinicians worldwide.
Josh Haas,Certified Personal Trainer and Nutrition Coach joins us to discuss how to ward off poor nutrition during a C. difficile infection and many other wellness-draining illnesses. Josh will share the importance of hydration and maintaining proper nutrition when diagnosed with a CDI and more.
Join us with guests Russ Stephens, VP Business Development and Michelle L. Vignari RN, CIC currently is the Director of Infection Prevention and Disaster Preparedness as they discuss dry hydrogen peroxide and the disinfection of any organism..
Join us with our guest Joe Martin, Executive Director of a Pennsylvania Health Care organization. Mr. Martin has more than 30 years of experience in the public relations field, including public, government and media relations, policy development, and non-profit fundraising for various organizations. Mr. Martin will be discussing C. difficile infections and Hospital Admissions through the years. He has been widely quoted in the academic, health care, and popular press internationally, in the US, and throughout Pennsylvania to discuss health care data and reports.
Join us with our guests, Lisa Hurka-Covington, Kathy Bischoff, Renetta Dudinski, and Veronica Edmond all C. diff. Survivors sharing their personal journey and road to recovery from a C. difficile infection. Nothing resonates more than the words shared from an individual who has been diagnosed, treated, and has recovered from this infection and other wellness-draining illnesses. If you have any questions for any of our guests, e-mail them to info@cdifffoundation.org and we look forward to answering them on the live broadcast.
Join us with our guest Dr. Arjun Srinivasan, an Infectious Disease Doctor and the Associate Director of Healthcare Associated Infection Prevention Programs for the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention in Atlanta, Georgia -- as we introduce Healthcare Associated Infections and discuss the progress being made to prevent them and the goals in place to eliminate HAI's.
Join us with our guest Dr. Arjun Srinivasan, an Infectious Disease Doctor and the Associate Director of Healthcare Associated Infection Prevention Programs for the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention in Atlanta, Georgia -- as we introduce Healthcare Associated Infections and discuss the progress being made to prevent them and the goals in place to eliminate HAI's.
Join Us With Guest Dr. Richard Vickers, Ph.D., Chief Scientific Officer at Summit Therapeutics joining us to discuss their research on a new antibiotic to treat a C. difficile infection. Learn more about Ridinilazole, clinical trials and the progress being made and moving closer to getting an urgently needed new treatment available for CDI to patients.
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
Join us with our guests Bruce Rippe, CEO of Trinity Guardion and J. Darrel Hicks, BA, Master REH, CHESP as we discuss HAIs and how they lead to more than 720,000 illnesses and 75,000 deaths a year. In fact, more people die from HAIs each year than from automobile accidents. Furthermore, HAIs are a huge financial burden, adding $30 billion to annual healthcare costs. The American-made Trinity Patient Protection System gives hospitals the solution they need to reduce and eliminate HAIs. Launderable, reusable, cost-effective and eco-friendly, the Trinity System’s fluid-proof covers fit around beds, pillows, stretchers and physical therapy tables. Unlike typical disinfectant agents designed for hard surfaces, the Trinity System keeps bacteria off the porous surface of the mattress, as well as, the bed deck. When laundered to CDC standards, the Trinity System removes 99.99% of bacteria and has been proven to reduce C. diff infection rates by about 50%.
Join us with our guest, Dr Mary Beth Dorr, PhD, Clinical Director, Clinical Research, Infectious Diseases, Merck & Co., Inc. as Mary Beth provides us with an overview of a C. diff. infection, the challenges of recurrence, latest clinical research overview, current treatment landscape, and pending new C. diff infection treatment guidelines from the Infectious Diseases Society of America (IDSA) that are anticipated to come out this fall.
Join us with our guests, Lisa Hurka-Covington, Kathy Bischoff, Renetta Dudinski, and Veronica Edmond all C. diff. Survivors sharing their personal journey and road to recovery from a C. difficile infection. Nothing resonates more than the words shared from an individual who has been diagnosed, treated, and has recovered from this infection and other wellness-draining illnesses. If you have any questions for any of our guests, e-mail them to info@cdifffoundation.org and we look forward to answering them on the live broadcast.
Richard Haupt, MD, Vice President, Medical Development Scientific & Clinical Affairs, at Pfizer where he serves as the global franchise lead for pipeline vaccines and Kathrin U. Jansen, PhD, Senior Vice President and head of Vaccine Research and Development at Pfizer Inc and Chris Webber, MD, Senior Director, Vaccines Clinical Research and Development. Dr. Webber is clinical program lead of the recently acquired meningococcal ACWY program from GSK, and is the clinical program lead for Pfizer’s Clostridium difficile vaccine. Our discussion will be focused on C. difficile Prevention: Evaluating the Role of Vaccines.
The Centers for Disease Control and Prevention (CDC) sounds the alarm on the danger of modern medicine returning to a time when simple infections were often fatal. As the latest Vital Signs Report shows, much progress has been made in our hospitals and healthcare facilities to protect patients from healthcare-associated infections. But, more work needs to be done, because many of these infections are caused by antibiotic-resistant bacteria which are difficult, if not impossible to treat. The CDC believes clinicians are key to national progress in preventing infections. They have the power to change the direction of antibiotic resistance each and every time they care for their patients. It requires taking the appropriate steps every time. We are in a race to slow resistance, and we can’t afford to let the “superbugs” outpace us, especially in healthcare settings.
In a recent study published by the Journal of the American Medical Association, new data was released showing that at least 30 percent of all prescriptions written in doctors’ offices and emergency rooms are completely unnecessary. So how do we use these alarming results to transform the culture of overprescribing? Dr. Katherine Fleming-Dutra, M.D., will: Give a detailed explanation of the study results, and provide an in-depth review of specific findings; Highlight what CDC is doing to promote antibiotic stewardship across healthcare settings, and Identify what clinicians, other health care professionals, and patients can do to improve antibiotic prescribing, therefore fighting antibiotic resistance.
Join us with our guest Barbara McGovern, MD. Since 2012 Dr. McGovern has been working within the pharmaceutical arena and currently is head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Their lead microbiome therapeutic drug is SER-109, which is being evaluated in a phase 3 clinical trial for recurrent Clostridium difficile infection. We will be discussing the role of the Microbiome in reducing the risk of C. diff. infection recurrence.
Join Us With Guest Dr. Richard Vickers, Ph.D., Chief Scientific Officer at Summit Therapeutics joining us to discuss their research on a new antibiotic to treat a C. difficile infection. Learn more about Ridinilazole, clinical trials and the progress being made and moving closer to getting an urgently needed new treatment available for CDI to patients.
Join us with our guest Barbara McGovern, MD. Since 2012 Dr. McGovern has been working within the pharmaceutical arena and currently is head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Their lead microbiome therapeutic drug is SER-109, which is being evaluated in a phase 3 clinical trial for recurrent Clostridium difficile infection. We will be discussing the role of the Microbiome in reducing the risk of C. diff. infection recurrence.
What impact does the quality of the air in a room have on airborne and surface bacteria?” Join us with our guest Dr. Linda D. Lee, DrPH, MBA, Ph.D.as we discuss contaminated air and how it can impact patients and the outcome during care.
Richard Haupt, MD, Vice President, Medical Development Scientific & Clinical Affairs, at Pfizer where he serves as the global franchise lead for pipeline vaccines and Kathrin U. Jansen, PhD, Senior Vice President and head of Vaccine Research and Development at Pfizer Inc and Chris Webber, MD, Senior Director, Vaccines Clinical Research and Development. Dr. Webber is clinical program lead of the recently acquired meningococcal ACWY program from GSK, and is the clinical program lead for Pfizer’s Clostridium difficile vaccine. Our discussion will be focused on C. difficile Prevention: Evaluating the Role of Vaccines.
Richard Haupt, MD, Vice President, Medical Development Scientific & Clinical Affairs, at Pfizer where he serves as the global franchise lead for pipeline vaccines and Kathrin U. Jansen, PhD, Senior Vice President and head of Vaccine Research and Development at Pfizer Inc and Chris Webber, MD, Senior Director, Vaccines Clinical Research and Development. Dr. Webber is clinical program lead of the recently acquired meningococcal ACWY program from GSK, and is the clinical program lead for Pfizer’s Clostridium difficile vaccine. Our discussion will be focused on C. difficile Prevention: Evaluating the Role of Vaccines.
In this episode Tex Kissoon, MD,a well-known doctor from Canada, will provide us with the insight into the global phenomenon of Sepsis. Sepsis affects more than 30 million lives per year yet it is almost unknown to the general public and is quite often misdiagnosed by medical professionals worldwide. The reasons of why that is with the why Sepsis is so deadly, and what you can do to increase Sepsis awareness-- will be discussed in the next 60 minutes. Dr. Kissoon is joined by Ray Schachter, a Sepsis survivor who has dedicated all of his available time to combating and raising awareness of Sepsis worldwide. Both are members of the Global Sepsis Alliance, which has established World Sepsis Day on September 13th every year to raise awareness for Sepsis worldwide.
Josh Haas,Certified Personal Trainer and Nutrition Coach joins us to discuss how to ward off poor nutrition during a C. difficile infection and many other wellness-draining illnesses. Josh will share the importance of hydration and maintaining proper nutrition when diagnosed with a CDI and more.
Join us with guests, Lori Strazdas, MPH and Dr. Charles Gerba, MD as they discuss how Schools are notorious for the spread of infectious organisms and C. difficile is a growing concern in the community. As our children return to the classroom for another school year, it is important to revisit best practices for cleaning facilities, disinfecting surfaces, and preventing infections that are commonly acquired in schools. In this episode, we will also discuss the increased risk posed to children in school environments and the specific infections that are prevalent in schools. We will discuss steps that schools can take to mitigate infection risks for their students and communities. You will also learn which specific disinfecting products to use in schools depending on what type of infections are recognized in your student population.
Join us with guests, Lori Strazdas, MPH and Dr. Charles Gerba, MD as they discuss how Schools are notorious for the spread of infectious organisms and C. difficile is a growing concern in the community. As our children return to the classroom for another school year, it is important to revisit best practices for cleaning facilities, disinfecting surfaces, and preventing infections that are commonly acquired in schools. In this episode, we will also discuss the increased risk posed to children in school environments and the specific infections that are prevalent in schools. We will discuss steps that schools can take to mitigate infection risks for their students and communities. You will also learn which specific disinfecting products to use in schools depending on what type of infections are recognized in your student population.
Join our guests Sue Barnes, RN, BSN, CIC, FAPIC and Wesley LaPorte a graduate of Brigham Young University in Life Sciences, as they discuss the role of contaminated environmental surfaces and the patient environment in healthcare settings. Mobile electronic devices, such as cell phones and computer tablets are improving the provision of healthcare but do entail unintended consequences coming in contact with contaminated surfaces harboring harmful germs. Learn more about the types of bacteria that can be transmitted, the healthcare environments, and the positive uses of UV light being used in healthcare environments addressing the prevention of transmission of germs throughout healthcare settings.
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
Join us with our guest, Dr Mary Beth Dorr, PhD, Clinical Director, Clinical Research, Infectious Diseases, Merck & Co., Inc. as Mary Beth provides us with an overview of a C. diff. infection, the challenges of recurrence, latest clinical research overview, current treatment landscape, and pending new C. diff infection treatment guidelines from the Infectious Diseases Society of America (IDSA) that are anticipated to come out this fall.
Join us with our guests Bruce Rippe, CEO of Trinity Guardion and J. Darrel Hicks, BA, Master REH, CHESP as we discuss HAIs and how they lead to more than 720,000 illnesses and 75,000 deaths a year. In fact, more people die from HAIs each year than from automobile accidents. Furthermore, HAIs are a huge financial burden, adding $30 billion to annual healthcare costs. The American-made Trinity Patient Protection System gives hospitals the solution they need to reduce and eliminate HAIs. Launderable, reusable, cost-effective and eco-friendly, the Trinity System’s fluid-proof covers fit around beds, pillows, stretchers and physical therapy tables. Unlike typical disinfectant agents designed for hard surfaces, the Trinity System keeps bacteria off the porous surface of the mattress, as well as, the bed deck. When laundered to CDC standards, the Trinity System removes 99.99% of bacteria and has been proven to reduce C. diff infection rates by about 50%.
Join us with our topic experts from the Centers for Disease Control and Prevention in Atlanta, Georgia, Dr. Clifford McDonald, CDC's Associate Director for Science in the Division of Healthcare Quality Promotion and Dr. Alison Laufer-Halpin, Team Lead in the Clinical and Environmental Microbiology Branch of the Division of Healthcare Quality Promotion. Doctors McDonald and Laufer-Halpin will be discussing the significant ways to unlock the mysteries of the microbiome and the role of the human microbiome; how it affects our health, the immune system, and why it's so important to protect it. If you have any questions prior to the live broadcast, email them to info@cdifffoundation.org and we will ask the topic experts joining us.
Join us with our guest James Psihas, a graduate Engineer of University of Arizona, as we discuss preventing cross contamination in a healthcare environment. Hand held devices such as phones, iPads, stethoscopes, glucometers, telemetry boxes and more travel from room to room picking up pathogens and become vectors of cross contamination that can result in healthcare acquired infections(HAI's) such as C.diff. and MRSA. Until the implementation of Dr. Wayne Clarks Advanced UV Systems technology developed for the department of defense to kill Anthrax hospitals the healthcare industry had very few tools available to consistently decontaminate these items without damaging expensive electronics.
Sanofi Pasteur, one of the leading vaccine manufacturers in the world, is in the midst of its Phase III clinical trial called Cdiffense to study its investigational vaccine to prevent Clostridium difficile infection (CDI). The trial is now in more than 20 countries across 5 continents to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary, symptomatic CDI. The investigational C. diff vaccine is designed to produce an immune response that targets the toxins generated by C. diff bacteria, which can cause inflammation of the gut. The investigative vaccine ultimately may help prevent a future infection from occurring. Volunteers for the study should be age 50 or older and planning an upcoming hospitalization or have had at least two hospital stays and have received systemic antibiotics in the past year. For more information on the Cdiffense trial, please visit www.Cdiffense.org
Join us with our guest, Dr. Joseph Sliman, MD, MPH, Chief Medical Officer of Synthetic Biologics as Dr. Sliman discusses the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of Clostridium difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).
Join our guest, Ron Romano, RN as we discuss Infection prevention - the guidelines and recommendations related to a healthcare-associated infection in multiple settings. Infection prevention and control is required to prevent the transmission of communicable diseases in all health care settings. Infection prevention and control demands a basic understanding of the epidemiology of diseases; risk factors that increase patient susceptibility to infection; and the practices, procedures and treatments that may result in infections. The guidelines and recommendations related to infection prevention. HAIs are currently one of the top ten leading causes of death in the United States. Healthcare professionals have an important role in HAI prevention.
Learning ways to reduce stress and manage time is helpful to the caregiver. People who neglect their own needs and forget to nurture themselves are at danger of falling into fatigue and high stress. There are important basic self care strategies that can keep you functioning well and ready for life's challenges. There are times when people spend their time only taking care of others can be at risk for getting burned out on all the giving, which makes it more difficult to care for others or themselves. Taking time to care for yourself regularly can make you a better caretaker for others. Join us with guests Linda Jablonski, MS,BSN,BC-RN, and Barbara Baker Schaefer, MSW, as we discuss several different ways to focus on self-care, the balance of leisure time in your schedule - making time for yourself, family, and friends.
This episode will provide foundational educational information about the microbiome by answering the fundamental questions of what is it, why is it important, how does it impact patients with C. difficile infections, and what are the possibilities of the microbiome as a therapeutic target for future drugs. This interview will be with Dr. Matthew Henn, Senior Vice President and Head of Drug Discovery & Bioinformatics at Seres Therapeutics, Inc,. Seres Therapeutics is a leading microbiome therapeutics company dedicated to creating a new class of medicines to treat diseases resulting from imbalances in the microbiome. These first-in-class drugs, called Ecobiotics®, are ecological compositions of beneficial organisms that are designed to restore a healthy human microbiome. The discovery efforts at Seres Therapeutics currently span metabolic, inflammatory, and infectious diseases.
Join us as Dr. Ron Daniels, MD and Dr. Imrana Malik, MD discuss Sepsis. Sepsis, one of the most prevalent but misdiagnosed, deadly diseases, was established as a global priority by the World Health Assembly, the decision-making body of the WHO, in the last week of May. In this episode, Dr Ron Daniels, Physician, Founder and CEO of the UK Sepsis Trust and Member of the Board of the Global Sepsis Alliance, and Dr Imrana Malik, Associate Professor in the Department of Critical Care at MD Anderson Cancer Center in Houston, TX, and Coordinator of GSA Advance, will explain why the resolution on sepsis is a milestone in the global fight against sepsis and what implications it will have.
Listen in as our guests Dr. Caterina Oneto, MD and Dr. Paul Feuerstadt, MD both specializing in Gastroenterology -- will be discussing IBD and what Inflammatory bowel disease (IBD) involves, including the chronic inflammation of all or part of the digestive tract. The Physicians will also be discussing signs and symptoms and diagnosing of a C. difficile Infection (CDI) along with the preventative measures, treatments available, and environmental safety products that can be utilized in a home setting. If you have any questions for the Physicians, e-mail us before the live broadcast at info@cdifffoundation.org and we will share the answers during the program.
Join us with our guests, Lisa Hurka-Covington, Kathy Bischoff, Renetta Dudinski, and Veronica Edmond all C. diff. Survivors sharing their personal journey and road to recovery from a C. difficile infection. Nothing resonates more than the words shared from an individual who has been diagnosed, treated, and has recovered from this infection and other wellness-draining illnesses. If you have any questions for any of our guests, e-mail them to info@cdifffoundation.org and we look forward to answering them on the live broadcast.
Join us with our guest, Dr. Joseph Sliman, MD, MPH, Chief Medical Officer of Synthetic Biologics as Dr. Sliman discusses the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of Clostridium difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).
Join our guest, Ron Romano, RN as we discuss Infection prevention - the guidelines and recommendations related to a healthcare-associated infection in multiple settings. Infection prevention and control is required to prevent the transmission of communicable diseases in all health care settings. Infection prevention and control demands a basic understanding of the epidemiology of diseases; risk factors that increase patient susceptibility to infection; and the practices, procedures and treatments that may result in infections. The guidelines and recommendations related to infection prevention. HAIs are currently one of the top ten leading causes of death in the United States. Healthcare professionals have an important role in HAI prevention.
Join us and our three guests, Bradley Whitchurch, Founder and Chairman of the Board at Seal Shield, LLC, Dr. Rosie D. Lyles, MD, Clinical Affairs Head, Research and Department, Clorox Healthcare and Shelby Lassiter, BSN, RN, CPHQ, CIC, an Infection Preventionist as they come together to discuss C. diff. infections, hospital-associated infections, and you will want to know why hand hygiene alone is not enough, plus infection prevention measures in the healthcare and home settings.
Join Steven D. Johnson, PA-C who has practiced in Internal Medicine and Geriatric Medicine departments for the last 34 years. Steven will be discussing the care of the senior population and patients in a skilled nursing setting for short-term rehabilitation services. There are many challenges encountered in a Skilled Nursing Setting and Steven will be sharing the experiences and positive goals of care for patients.
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.
Listen in as our guests Dr. Caterina Oneto, MD and Dr. Paul Feuerstadt, MD both specializing in Gastroenterology -- will be discussing IBD and what Inflammatory bowel disease (IBD) involves, including the chronic inflammation of all or part of the digestive tract. The Physicians will also be discussing signs and symptoms and diagnosing of a C. difficile Infection (CDI) along with the preventative measures, treatments available, and environmental safety products that can be utilized in a home setting. If you have any questions for the Physicians, e-mail us before the live broadcast at info@cdifffoundation.org and we will share the answers during the program.
Join us with our guest Linda Jablonski, MSN, BSN, BC-RN, as we discuss becoming an effective self-advocate and how to advocate for others. It is about asking the right questions, when to seek clarification when topics are not understood and how to make sure their values and goals are part of the discussion.For a significant percentage of people facing any serious illness, becoming an effective self-advocate poses a range of challenges. Get a piece of paper and pencil ready, the iPad works well also, and a few notes will go a long way in the path of advocating in healthcare.
Listen in as our guest Shelby Lassiter, BSN,RN,CPHQ,CIC, Infection Preventionist, joins us to discuss the many ways on how to maintain infection control in a home environment while treating a C. diff. infection. That means how to eliminate the C. diff. spores and more!
Sanofi Pasteur's Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines. Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. These three Sanofi Pasteur professionals will discuss the background of acquiring a C.difficile infection, Sanofi Pasteur's vaccine (Cdiffense) program, and the data from the preventative vaccine in Phase II.
Listen in as our guest Shelby Lassiter, BSN,RN,CPHQ,CIC, Infection Preventionist, joins us to discuss the many ways on how to maintain infection control in a home environment while treating a C. diff. infection. That means how to eliminate the C. diff. spores and more!
Join us with guests Jenna Petelle Arsenault, MSW, RN and Janice Howard,Director of the Life Care – Private Duty Program at Cornerstone VNA. Both Jenna and Janice will be discussing the importance of the Caregiver and description of a Caregiver's role. We know that with an increasingly aging population in all developed societies, the role of caregiver has been increasingly recognized as an important one, both functionally and economically. Many organizations which provide support for persons with disabilities have developed various forms of support for carers as well.
Join our guest, Linda Jablonski, MS,BSN,RN-BC as we discuss caring for patients and families in the home care setting, Nurses specializing in Home Care, and preventing infections within the home environment. There will be something new to learn during this episode from team members to patients.
Join us as Dr. Dale Gerding, MD, an Infectious Disease specialist, researcher, professor, hospital epidemiologist, and one of the leading international experts on Clostridium diffiicle (C.diff.), will discuss his patented non-toxigenic Clostridium difficile (NTCD-M3) technology for the prevention and treatment of a C. diff. infection. Dr.Gerding currently owns patents and all rights to the development, manufacturing, regulatory, and clinical trial data for NTCD-M3. The lead pharmaceutical product, NTCD-M3, incorporating this technology has already completed Phase 1 & 2 Clinical Trials, has FDA Fast Track approval, is expected to be eligible for Breakthrough Therapy Designation by the FDA for a Phase 3 Clinical Trial, and to be eligible for Reference Product Exclusivity for 12 years for an approved biologics license application.
Join us as Dr. Dale Gerding, MD, an Infectious Disease specialist, researcher, professor, hospital epidemiologist, and one of the leading international experts on Clostridium diffiicle (C.diff.), will discuss his patented non-toxigenic Clostridium difficile (NTCD-M3) technology for the prevention and treatment of a C. diff. infection. Dr.Gerding currently owns patents and all rights to the development, manufacturing, regulatory, and clinical trial data for NTCD-M3. The lead pharmaceutical product, NTCD-M3, incorporating this technology has already completed Phase 1 & 2 Clinical Trials, has FDA Fast Track approval, is expected to be eligible for Breakthrough Therapy Designation by the FDA for a Phase 3 Clinical Trial, and to be eligible for Reference Product Exclusivity for 12 years for an approved biologics license application.
Listen in as our guest, Dr. Deverick J. Anderson, MD, Director, Duke Center for Antimicrobial Stewardship and Infection Prevention, Associate Professor of Medicine, Division of Infectious Diseases, discusses the BETR-D study and UV disinfecting combating VRE, MRSA, C. difficile, and MDR acetin obacter. Dr. Anderson also discusses Antimicrobial Stewardship and Infection Prevention strategies.
Join us as Dr. Hudson Garrett discusses key points focused on the importance of an informed patient and ways to prevent healthcare associated infections. Dr. Garrett will also provide an in depth view of patients and the importance of collaborating with healthcare providers to reduce the risks of infections.
In a recent study published by the Journal of the American Medical Association, new data was released showing that at least 30 percent of all prescriptions written in doctors’ offices and emergency rooms are completely unnecessary. So how do we use these alarming results to transform the culture of overprescribing? Dr. Katherine Fleming-Dutra, M.D., will: Give a detailed explanation of the study results, and provide an in-depth review of specific findings; Highlight what CDC is doing to promote antibiotic stewardship across healthcare settings, and Identify what clinicians, other health care professionals, and patients can do to improve antibiotic prescribing, therefore fighting antibiotic resistance.
Listen in as our guest, Dr. Deverick J. Anderson, MD, Director, Duke Center for Antimicrobial Stewardship and Infection Prevention, Associate Professor of Medicine, Division of Infectious Diseases, discusses the BETR-D study and UV disinfecting combating VRE, MRSA, C. difficile, and MDR acetin obacter. Dr. Anderson also discusses Antimicrobial Stewardship and Infection Prevention strategies.
This episode is focused on using antibiotics wisely and how YOU can help in the fight of antibiotic resistance. Listen in as these two stellar Physicians discuss the topics of Clostridium difficile infections and Antibiotic usage. Important topics for citizens on a global level.
This episode will provide foundational educational information about the microbiome by answering the fundamental questions of what is it, why is it important, how does it impact patients with C. difficile infections, and what are the possibilities of the microbiome as a therapeutic target for future drugs. This interview will be with Dr. Matthew Henn, Senior Vice President and Head of Drug Discovery & Bioinformatics at Seres Therapeutics, Inc,. Seres Therapeutics is a leading microbiome therapeutics company dedicated to creating a new class of medicines to treat diseases resulting from imbalances in the microbiome. These first-in-class drugs, called Ecobiotics®, are ecological compositions of beneficial organisms that are designed to restore a healthy human microbiome. The discovery efforts at Seres Therapeutics currently span metabolic, inflammatory, and infectious diseases.
Join us as we discuss a promising and new treatment for a C. difficile infection. Summit Therapeutic's Ridinilazole, a microbiome preserving antibiotic will be introduced with updates by our two guests Dr. Kevin W. Garey, Chair, Department of Pharmacy Practice and Translational Research, Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas and Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics..
Join us as we discuss a promising and new treatment for a C. difficile infection. Summit Therapeutic's Ridinilazole, a microbiome preserving antibiotic will be introduced with updates by our two guests Dr. Kevin W. Garey, Chair, Department of Pharmacy Practice and Translational Research, Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas and Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics..
Join us as we discuss the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Recent clinical data suggest that the absence or abundance of certain microbes may be directly linked to certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel syndrome (IBS). Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 2 development including, SYN-004 which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of CDI, AAD and the emergence of antibiotic-resistant organisms, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).
Learn about the importance of laboratory testing in the identification of a C. difficile Infection (CDI). with guests: Jeanine Thomas, President and Founder of the MRSA Survivors Network who is a survivor of both MRSA and C. diff. infections. Dr. Nathan A. Ledeboer, PhD, D(ABMM), Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health. Dr. Whitney R. Buckel, PharmD, BCPS who is the Infectious Diseases and Antimicrobial Stewardship Clinical Pharmacist at Intermountain Medical Center, and Dr. Steven Cagas, who will give us a brief overview of Roche Diagnostics as well as their new cobas® Cdiff Test.
Join us and our three guests, Bradley Whitchurch, Founder and Chairman of the Board at Seal Shield, LLC, Dr. Rosie D. Lyles, MD, Clinical Affairs Head, Research and Department, Clorox Healthcare and Shelby Lassiter, BSN, RN, CPHQ, CIC, an Infection Preventionist as they come together to discuss C. diff. infections, hospital-associated infections, and you will want to know why hand hygiene alone is not enough, plus infection prevention measures in the healthcare and home settings.
C.diff Spores and More discuss current C.difficile infection objectives for hospitals within the United Kingdom with James McIlroy, a medical student and founder of a not-for-profit stool bank based within the University of Aberdeen in Scotland.
C. diff. Spores and More discuss Rebiotix and their clinical study with Rebiotix Founder, CEO Lee Jones. Listen in as we learn more about the History, Company profile, Problems they are solving,and product information. Lee will explain What is the microbiome? Their first product RBX 2660 – addressing C. diff, with the Rebiotix platform called MRT (Microbiota Restoration Therapy) and how MRT is different.
This episode we will discuss An Oral Vaccine for C. difficile Infection with Professor Simon Cutting from the Royal Holloway, University of London in the UK, and Chairperson of the C Diff Foundation's Research and Development Committee and Research Community. Follow us as we discuss the probable causes of C. diff. infection and why it is so prevalent in today's society. Learn what is required to prevent C. diff. infections, and gain a better understanding of the research being focused towards creating prevention against this life-threatening infection; Clostridium difficile.
Join us as guest, and co-founder of Xenex, Dr. Mark Stibich Epidemiologist and Chief Scientific Officer, discusses UV Disinfection with Xenex UV Disinfecting Systems + Robots making a clean sweep across the globe zapping #Cdiff and all harmful germs that can cause pain, suffering, and double digits in the already stressed healthcare industry. #Cdiff Spores and More #CdiffRadio bringing you educational episodes. None of us can do this alone -- All of us can do this together.
Join us as Dr. Hudson Garrett discusses effective ways being used to prevent acquiring a C. difficile infection (CDI) and Carbapenem-resistant Enterobacteriaceae (CRE), treatments available, and environmental safety - infection prevention in hospitals, long-term care, and at home.
Dr. Garrett is a recognized international expert in infection prevention and control. Dr Garrett currently serves as the Chair of the Education Committee for the C Diff Foundation and is a graduate of the Johns Hopkins Fellows Program in Infection Control and Hospital Epidemiology. He was honored as a Who’s Who for Infection Control by Infection Control Today Magazine in 2013 in recognition of his contributions to the field.
This episode of “C. diff. Spores and More” is focused on What is IBS? So you've been diagnosed with IBS (Irritable Bowel Sydrome). Now what? Join us for a discussion about the definition, diagnosis, and treatment of the various forms of IBS with our special guests: Dr. Caterina Oneto,, MD and Dr. Paul Feuerstadt, MD, Both professors and physicians specializing in Gastroenterology with a wealth of knowledge and experience treating patients diagnosed with a CDI and through ongoing scientific/medical research.
In this episode Sepsis will be defined by three Healthcare Clinicians and one Clinician -- a Sepsis survivor. According to the CDC’s National Center for Health Statistics estimates that, based upon information collected for billing purposes, the number of times people were in the hospital with sepsis or septicemia (another word for sepsis) increase.Sepsis is a potentially life-threatening complication of an infection. If sepsis progresses to septic shock, blood pressure drops dramatically, which may lead to death. Anyone can develop sepsis, but it’s most common and most dangerous in older adults or those with weakened immune systems. Early treatment of sepsis improves chances for survival.
Join us with our guest,Cheryl Jones, a grief counselor and a cancer educator and C. diff. survivor, as we discuss anxiety, depression, and grief. Chronic physical illness also defined as a medical condition that lasts for a year or more, have also been experienced by many individuals diagnosed with a C. difficile infection. Patients can become depleted in patience and tolerance from an illness, resulting in a disruption of normal day to day activities due to limited mobility and/or loss of in dependency or from the loss of a loved one. The individual may experience feelings of frustration, anger and even grief. A sense of hopelessness may follow. Like other chronic medical conditions, individuals diagnosed with C. diff.,are also at risk for developing clinical depression and anxiety. Listen in as Cheryl provides information educating those who are struggling through physical limitations and personal losses.
This episode of “C. diff. Spores and More” is focused on “C. difficile Infections; The What, Where and How.” What is it, What can be done to prevent acquiring it, Where is it acquired, Where can clinicians and patients learn more about this infection, How is it being prevented at home and in the hospitals, How CDI’s are being treated, and How to learn more about the prevention, treatments, and environmental safety products available With our special guests: Dr. Caterina Oneto,, MD and Dr. Paul Feuerstadt, MD, Both professors and physicians specializing in Gastroenterology with a wealth of knowledge and experience treating patients diagnosed with a CDI and through ongoing scientific/medical research.
In this episode Tex Kissoon, MD,a well-known doctor from Canada, will provide us with the insight into the global phenomenon of Sepsis. Sepsis affects more than 30 million lives per year yet it is almost unknown to the general public and is quite often misdiagnosed by medical professionals worldwide. The reasons of why that is with the why Sepsis is so deadly, and what you can do to increase Sepsis awareness-- will be discussed in the next 60 minutes. Dr. Kissoon is joined by Ray Schachter, a Sepsis survivor who has dedicated all of his available time to combating and raising awareness of Sepsis worldwide. Both are members of the Global Sepsis Alliance, which has established World Sepsis Day on September 13th every year to raise awareness for Sepsis worldwide.
According to the Centers for Disease Control and Prevention (CDC) report published in February 2015, almost 500,000 C.diff. infections occurred in the U.S. in 2011, with 83,000 recurrences. Join our guests, C. diff. survivors, Heather Clark, Veronica Edmond, Renetta Dudzinski, and Lisa Hurka-Covington as they bravely share their story and unique journey through a C. diff. infection that forever changed their lives.
The Centers for Disease Control and Prevention (CDC) sounds the alarm on the danger of modern medicine returning to a time when simple infections were often fatal. As the latest Vital Signs Report shows, much progress has been made in our hospitals and healthcare facilities to protect patients from healthcare-associated infections. But, more work needs to be done, because many of these infections are caused by antibiotic-resistant bacteria which are difficult, if not impossible to treat. The CDC believes clinicians are key to national progress in preventing infections. They have the power to change the direction of antibiotic resistance each and every time they care for their patients. It requires taking the appropriate steps every time. We are in a race to slow resistance, and we can’t afford to let the “superbugs” outpace us, especially in healthcare settings.
This episode introduces Seres Therapeutics, a leading microbiome therapeutics company, which recently published in the Journal of Infectious Diseases positive results from an open-label Phase 1b/2 study of SER-109 for the treatment of patients with recurrent C. difficile infections (CDI). Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. New insights into the human microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, creating new possibilities for patients not served by current therapeutic approaches. Ecobiotics are ecological compositions of beneficial organisms that are designed to reestablish a healthy microbiome. The discovery efforts at Seres Therapeutics currently span metabolic, inflammatory, and infectious diseases. This interview will include forward-looking statements on Seres Therapeutics current expectations and projections about future events. These statements are based upon current beliefs, expectations and assumptions, and are subject to a number of important risks and uncertainties, including those set forth in Seres Therapeutics filings with the SEC, many of which are difficult to predict. Actual results may differ materially from such statements. The information included in this interview is provided only as of the date of this interview, and Seres Therapeutics undertakes no obligation to update any forward-looking statements stated in this interview on account of new information, future events, or otherwise, except as required by law. Seres Therapeutics has provided financial support to the C Diff Foundation.
Join us with our guest Glenn Taylor - Microbiologist at the Taymount Clinic just outside London in the UK. Glenn has spent five years researching the commensal colonization of bacteria in the human digestive system. The Taymount Clinic are known internationally as a specialist center for the production of tested, certified, high quality gut bacteria and effective, efficient implant techniques Researching intestinal bacteria since 2006, the Taymount Clinic is now a recognized world leader in applying Fecal / Faecal Microbiota Transplant or FMT treatment procedures to create a “normal” bacterial environment in patients with a broad range of conditions. The Taymount clinic provides FMT treatment to normalize gut bacteria in patients with a Clostridium difficile infection.
Sanofi Pasteur, one of the leading vaccine manufacturers in the world, is in the midst of its Phase III clinical trial called Cdiffense to study its investigational vaccine to prevent Clostridium difficile infection (CDI). The trial is now in more than 20 countries across 5 continents to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary, symptomatic CDI. The investigational C. diff vaccine is designed to produce an immune response that targets the toxins generated by C. diff bacteria, which can cause inflammation of the gut. The investigative vaccine ultimately may help prevent a future infection from occurring. Volunteers for the study should be age 50 or older and planning an upcoming hospitalization or have had at least two hospital stays and have received systemic antibiotics in the past year. For more information on the Cdiffense trial, please visit www.Cdiffense.org
This episode introduces Seres Therapeutics, a leading microbiome therapeutics company, which recently published in the Journal of Infectious Diseases positive results from an open-label Phase 1b/2 study of SER-109 for the treatment of patients with recurrent C. difficile infections (CDI). Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. New insights into the human microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, creating new possibilities for patients not served by current therapeutic approaches. Ecobiotics are ecological compositions of beneficial organisms that are designed to reestablish a healthy microbiome. The discovery efforts at Seres Therapeutics currently span metabolic, inflammatory, and infectious diseases.brbr This interview will include forward-looking statements on Seres Therapeutics current expectations and projections about future events. These statements are based upon current beliefs, expectations and assumptions, and are subject to a number of important risks and uncertainties, including those set forth in Seres Therapeutics filings with the SEC, many of which are difficult to predict. Actual results may differ materially from such statements. The information included in this interview is provided only as of the date of this interview, and Seres Therapeutics undertakes no obligation to update any forward-looking statements stated in this interview on account of new information, future events, or otherwise, except as required by law. Seres Therapeutics has provided financial support to the C Diff Foundation.
Join us as Dr. Hudson Garrett discusses effective ways being used to prevent acquiring a C. difficile infection (CDI) and Carbapenem-resistant Enterobacteriaceae (CRE), treatments available, and environmental safety - infection prevention in hospitals, long-term care, and at home. br Dr. Garrett is a recognized international expert in infection prevention and control. Dr Garrett currently serves as the Chair of the Education Committee for the C Diff Foundation and is a graduate of the Johns Hopkins Fellows Program in Infection Control and Hospital Epidemiology. He was honored as a Who’s Who for Infection Control by Infection Control Today Magazine in 2013 in recognition of his contributions to the field.
This episode is focused on using antibiotics wisely and how YOU can help in the fight of antibiotic resistance. Listen in as these two stellar Physicians discuss the topics of Clostridium difficile infections and Antibiotic usage. Important topics for citizens on a global level.
This episode introduces XBiotech, developer of True Human(TM) therapeutic antibodies. XBiotech has an exciting pipeline of product candidates in various areas of medicine. The Company recently announced the launch of a research and development program to develop a first-in-class oral monoclonal antibody against Clostridium difficile (C.difficile) infection. The Company will discuss the need for an effective C.difficile therapy, their novel approach to treating the disease as well as efficiency in their manufacturing technology. Join guests: Dr. Michael Stecher, Medical Director, Dr. Sushma Shivaswamy, Vice President of Research and Development, and Kelly Thornburg, Senior Vice President of Operations, as they discuss how XBiotech is pioneering a new era in the discovery and development of targeted antibodies therapeutics.
Listen in as our guest Shelby Lassiter, BSN,RN,CPHQ,CIC, Infection Preventionist, joins us to discuss the many ways on how to maintain infection control in a home environment while treating a C. diff. infection. That means how to eliminate the C. diff. spores and more!
This episode of “C. diff. Spores and More” is focused on “C. difficile Infections; The What, Where and How.” What is it, What can be done to prevent acquiring it, Where is it acquired, Where can clinicians and patients learn more about this infection, How is it being prevented at home and in the hospitals, How CDI’s are being treated, and How to learn more about the prevention, treatments, and environmental safety products available With our special guests: Dr. Caterina Oneto,, MD and Dr. Paul Feuerstadt, MD, Both professors and physicians specializing in Gastroenterology with a wealth of knowledge and experience treating patients diagnosed with a CDI and through ongoing scientific/medical research.
Listen in as our guest Shelby Lassiter, BSN,RN,CPHQ,CIC, Infection Preventionist, joins us to discuss the many ways on how to maintain infection control in a home environment while treating a C. diff. infection. That means how to eliminate the C. diff. spores and more!
Join us to hear from Merck's Dr. Nick Kartsonis, and the history in addressing infectious disease and antimicrobial resistance. Dr. Nick Kartsonis will also be discussing the future in the area of C. diff. and some of the company's current treatments, including DIFICID and their ongoing research addressing CDI.
According to the Centers for Disease Control and Prevention (CDC) report published in February 2015, almost 500,000 C.diff. infections occurred in the U.S. in 2011, with 83,000 recurrences. Join our guests, C. diff. survivors, Heather Clark, Veronica Edmond, Renetta Dudzinski, and Lisa Hurka-Covington as they bravely share their story and unique journey through a C. diff. infection that forever changed their lives.
Join us and learn from our guests; Dr. Clifford McDonald, MD, Senior Advisor for Science and Integrity, Division of Healthcare Quality Promotion at the CDC with main interests in epidemiology and prevention of Healthcare-Associated Infections, especially Clostridium difficile infections, and the prevention of antimicrobial resistance. And Dr. Arjun Srinivasan, MD, Associate Director for Healthcare-Associated Infection prevention programs in the Division of Healthcare Quality Promotion at CDC's National Center for Emerging and Zoonotic Infectious Disease. Listen in as these two stellar Physicians discuss the topics of Clostridium difficile infections and Antibiotic usage, two important issues with potential solutions facing the citizens on a global level..
Join us and our three guests, Bradley Whitchurch, Founder and Chairman of the Board at Seal Shield, LLC, Dr. Rosie D. Lyles, MD, Clinical Affairs Head, Research and Department, Clorox Healthcare and Shelby Lassiter, BSN, RN, CPHQ, CIC, an Infection Preventionist as they come together to discuss C. diff. infections, hospital-associated infections, and you will want to know why hand hygiene alone is not enough, plus infection prevention measures in the healthcare and home settings.
Dr. Mark Stibich, PhD, Chief Scientific Officer & Co-founder, Xenex. and Ms. Sarah Simmons, MPH CIC, Science Director, Xenex discuss pulsed xenon UV light room disinfection technology. Dr. Stibich and Ms. Simmons will share information how pulsed UV disinfection works, the pulsed Xenon UV (PX-UV) difference, and the effectiveness against endospores like C. diff. and bacillus strains and more.
The majority of C. difficile cases are caused by the unintended consequences of antibiotic therapy to the gut microbiome. Intravenous (IV) antibiotics excreted to the gut often wipe out the natural balance of microflora, which can lead to recurring diarrhea and perforation of the intestinal wall, with potentially fatal outcomes. Co-administered with IV antibiotics, Synthetic Biologics’ product candidate, SYN-004, is designed to be a preventive therapy intended to protect the gut microbiome by degrading IV antibiotics, thereby preventing the onset of C. difficile infection. Synthetic Biologics, Inc.’s Lewis Barrett, BS, MBA, Senior Vice President, Commercial Strategy and Joseph A. Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs will discuss the novel point-of-care preventive approach, the clinical development pathway and the potential of the Company’s lead pathogen-specific product candidate, SYN-004.
Lee Jones, Founder, President and CEO of Rebiotix Inc, has over thirty years of experience in the medical technology industry in large and small companies and academia. Rebiotix is developing a new category of biologic drugs that use live human-derived organisms to treat disease. Lead candidate RBX2660 (microbiota suspension) is currently undergoing clinical study for recurrent C. diff. infection. Glenn Taylor is the Microbiologist at the Taymount Clinic just outside London in the UK. He has spent five years researching the commensal colonization of bacteria in the human digestive system. Listen in as both guests discuss the Fecal or Faecal Microbiota Transplant (FMT),also known as Microbiota Restoration Therapy to treat recurrent C. diff. infections and more – Research to Clinical
Professor Sheridan, C. diff. Survivor and FMT Patient : Nancy Sheridan is a full time, Associate Professor at the Fashion Institute of Technology and a winner of the prestigious SUNY Chancellor’s Award for Excellence in Teaching. Professor Sheridan has been teaching since fall 2000 in the Fashion Merchandising Management Department within the School of Business and Technology. For the past seven years, she has also taught a Retail Merchandising course at the University of Pennsylvania, Wharton Business School to undergraduate and MBA students. In June of 2014, Nancy had surgery and contracted c.diff while in the hospital, suffered 5 c.diff reoccurrences from June to December 2014 in January she received a Fecal Microbiota Transplant and has been c diff free since.
The majority of C. difficile cases are caused by the unintended consequences of antibiotic therapy to the gut microbiome. Intravenous (IV) antibiotics excreted to the gut often wipe out the natural balance of microflora, which can lead to recurring diarrhea and perforation of the intestinal wall, with potentially fatal outcomes. Co-administered with IV antibiotics, Synthetic Biologics’ product candidate, SYN-004, is designed to be a preventive therapy intended to protect the gut microbiome by degrading IV antibiotics, thereby preventing the onset of C. difficile infection. Synthetic Biologics, Inc.’s Lewis Barrett, BS, MBA, Senior Vice President, Commercial Strategy and Joseph A. Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs will discuss the novel point-of-care preventive approach, the clinical development pathway and the potential of the Company’s lead pathogen-specific product candidate, SYN-004.
Sanofi Pasteur's Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines. Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. These three Sanofi Pasteur professionals will discuss the background of acquiring a C.difficile infection, Sanofi Pasteur's vaccine (Cdiffense) program, and the data from the preventative vaccine in Phase II.
Sanofi Pasteur's Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines. Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. These three Sanofi Pasteur professionals will discuss the background of acquiring a C.difficile infection, Sanofi Pasteur's vaccine (Cdiffense) program, and the data from the preventative vaccine in Phase II.
Key Scientific Researchers, Dr. Casey Theriot of University of Michigan will be discussing the latest research how C. difficile wreaks havoc on the guts of animals in a short time, and causes severe diarrhea and life-threatening disease in humans. and Dr. Matha Clokie of University of Leicester UK will also be discussing the most recent work in the are of C. difficile research.
Nancy C. Caralla, the C Diff Foundation's Founding Executive Director and Dr. Chandrabali Ghose, Chairperson of Research and Development introduce the first episode of C. diff. Spores and More. As advocates for C. diff. infection prevention, treatments, and environmental safety, we are excited to launch this cutting-edge new weekly radio show and what it means for our Foundation’s community worldwide.